Provision of safe donor pigs for xenotransplantation by Egerer, Stefanie Bettina
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provision of safe donor pigs for xenotransplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
von Stefanie Bettina Egerer 
  
 
 
Inaugural-Dissertation zur Erlangung der Doktorwürde 
der Tierärztlichen Fakultät der Ludwig-Maximilians- 
Universität München 
 
 
 
 
 
 
 
 
Provision of safe donor pigs for xenotransplantation 
 
 
 
 
 
 
 
 
 
 
 
von Stefanie Bettina Egerer 
aus Illertissen 
München 2020 
 
Aus dem Veterinärwissenschaftlichen 
Department der Tierärztlichen Fakultät 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
Lehrstuhl für Molekulare Tierzucht und Biotechnologie 
 
 
 
 
 
 
 
 
 
Arbeit angefertigt unter der Leitung von Univ.-Prof. Dr. Eckhard Wolf 
 
 
 
 
 
 
 
Mitbetreuung durch: Priv.-Doz. Dr. Nikolai Klymiuk 
und Dr. Andrea Bähr 
 
  
 
Gedruckt mit Genehmigung der Tierärztlichen Fakultät 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
 
Dekan: Univ.-Prof. Dr. Reinhard K. Straubinger, Ph.D. 
Berichterstatter: Univ.-Prof. Dr. Eckhard Wolf 
Korreferent/en: Univ.-Prof. Dr. Gerd Sutter 
Univ.-Prof. Dr. Ralf S. Müller 
Prof. Dr. Gerhard Wess 
Priv.-Doz. Dr. Rebecca Kenngott 
 
 
 
 
 
 
 
Tag der Promotion: 08. Februar 2020 
 
  
 
 
 
 
 
 
 
 
 
 
Für meine liebe Familie 
 
 During preparation of this thesis the following papers have been published: 
 
 
 
Egerer S, Fiebig U, Kessler B, Zakhartchenko V, Kurome M, Reichart B, Kupatt C, Klymiuk N, 
Wolf E, Denner J, Bähr A. Early weaning completely eliminates porcine cytomegalovirus from 
a newly established pig donor facility for xenotransplantation. Xenotransplantation. 2018 
Jul;25(4):e12449. doi: 10.1111/xen.12449. 
 
 
Längin M, Mayr T, Reichart B, Michel S, Buchholz S, Guethoff S, Dashkevich A, Baehr A, Egerer 
S, Bauer A, Mihalj M, Panelli A, Issl L, Ying J, Fresch AK, Buttgereit I, Mokelke M, Radan J, 
Werner F, Lutzmann I, Steen S, Sjöberg T, Paskevicius A, Qiuming L, Sfriso R, Rieben R, Dahlhoff 
M, Kessler B, Kemter E, Kurome M, Zakhartchenko V, Klett K, Hinkel R, Kupatt C, Falkenau A, 
Reu S, Ellgass R, Herzog R, Binder U, Wich G, Skerra A, Ayares D, Kind A, Schönmann U, Kaup 
FJ, Hagl C, Wolf E, Klymiuk N, Brenner P, Abicht JM. Consistent success in life-supporting 
porcine cardiac xenotransplantation. Nature. 2018 Dec;564(7736):430-433. doi: 
10.1038/s41586-018-0765-z. 
 
 
Kurome M, Baehr A, Simmet K, Jemiller EM, Egerer S, Dahlhoff M, Zakhartchenko V, 
Nagashima H, Klymiuk N, Kessler B, Wolf E. Targeting αGal epitopes for multi-species embryo 
immunosurgery. Reprod Fertil Dev. 2019 Apr;31(4):820-826. doi: 10.1071/RD18120. 
 
 
Krüger L, Längin M, Reichart B, Fiebig U, Kristiansen Y, Prinz C, Kessler B, Egerer S, Wolf E, 
Abicht JM, Denner J. Transmission of Porcine Circovirus 3 (PCV3) by Xenotransplantation of 
Pig Hearts into Baboons. Viruses. 2019 Jul 16;11(7). pii: E650. doi: 10.3390/v11070650. 
 
ABBREVIATIONS XII 
 
 
Abbreviations 
 
αGal galactose α-1,3 galactose 
 
AAALAC Association for Assessment and Accreditation of Laboratory Animal Care 
 
AHXR acute humoral xenograft rejection 
AIDS acquired immune deficiency syndrome 
ASLV avian sarcoma/leukosis virus 
ATMP Advanced Therapy Medicinal Product 
 
BaPAR-2 baboon PERV-A receptor 2 
 
bp base pair 
 
BHK-21 baby hamster kidney cell line 
 
°C degree Celsius 
 
Cas CRISPR-associated 
 
CiMM Center for innovative Medical Models 
 
CMAH cytidine-monophosphate-N-acetyl-neuraminic acid hydroxylase 
 
CPB cardiopulmonary-bypass 
 
CRC TRR 127 Transregional Collaborative Research Center 127 (short “SFB” for the German 
“Sonderforschungsbereich”) 
CRISPR clustered regularly interspaced short palindromic repeats 
 
CXTx cardiac xenotransplantation 
 
DPF designated pathogen- free 
 
DMD Duchenne muscular dystrophy 
 
DNA deoxyribonucleic acid 
 
e.g. exempli gratia 
 
ECM decellularized extracellular matrix 
ABBREVIATIONS XIII 
 
 
EDTA Ethylendiamintetraazetat 
 
EMA European Medicines Agency 
 
env envelope 
 
ERV endogenous retrovirus 
 
ET embryo transfer 
 
etc. et cetera 
 
EtOH Ethanol 
 
FASS Federation of Animal Science Societies 
 
FCS fetal calf serum 
 
FDA Food and Drug Administration 
 
FELASA Federation of European Laboratory Animal Science Associations 
 
FeLV feline leukemia virus 
 
GaLV gibbon ape leukemia virus 
GGTA1 α-1,3-galactosyltransferase 
gm genetically-modified 
GMP good manufacturing practice 
 
GTKO GGTA1 knock-out 
 
GV-SOLAS Gesellschaft für Versuchstierkunde / Society of Laboratory Animal Science 
 
H2O water 
 
HAR hyperacute xenograft rejection 
 
hCD46 human membrane cofactor protein CD46 
 
hCD55 human decay acceleration factor CD55 
 
hCD59 human membrane inhibitor of reactive lysis  CD59 
 
HCV hepatitis C virus 
ABBREVIATIONS XIV 
 
 
hCXTx heterotopic cardiac xenotransplantation 
 
HEV Hepatitis E virus 
 
HEK human embryonic kidney 
 
HIV human immunodeficiency virus 
 
HLA human leucocyte antigens 
 
hTBM human thrombomodulin 
HuPAR-1 human PERV-A receptor 1 
HuPAR-2 human PERV-A receptor 2 
HUVECs human umbilical vein endothelial cells 
 
ICM inner cell mass 
 
ICTV International Committee on Taxonomy of Viruses 
 
IHC immunohistochemistry 
 
iPSCs induced pluripotent stem cells 
 
ISHLT International Society for Heart and Lung Transplantation 
 
IVF in vitro fertilization 
 
IXA International Xenotransplantation Association 
 
KoRV koala retrovirus 
 
LTR long terminal repeat 
 
LVG Lehr- und Versuchsgut Oberschleißheim 
 
MABB Chair for Molecular Animal Breeding and Biotechnology 
 
MCS mechanical circulatory support 
 
ml milliliter 
 
MLV murine leukemia virus 
 
mM millimolar 
ABBREVIATIONS XV 
 
 
µl microliter 
 
µM micromolar 
 
MoMLV Moloney Murine Leukemia Virus 
Neu5Ac N-acetyl-5-neuraminic acid 
Neu5Gc N-5-glycolyl-neuraminic acid 
NHDFs normal dermal human fibroblasts 
NRC National Research Council 
oCXTx orthotopic cardiac xenotransplantation 
PBMCs peripheral blood mononuclear cells 
PCMV porcine cytomegalovirus 
PDNS porcine dermatitis and nephropathy syndrome 
 
PEI Paul-Ehrlich-Institut 
 
PERV-A porcine endogenous retrovirus A 
PERV-B porcine endogenous retrovirus B 
PERV-C porcine endogenous retrovirus C 
PERVs porcine endogenous retroviruses 
PCV1 porcine circovirus type 1 
PCV2 porcine circovirus type 2 
 
PCV3 porcine circovirus 3 
 
PHS U.S. Public Health Service 
 
PoPAR porcine PERV-A receptor 
 
PSC pluripotent stem cell 
 
RNA ribonucleic acid 
 
rpm rounds per minute 
ABBREVIATIONS XVI 
 
 
 
RT reverse transcriptase 
SARS severe acute respiratory syndrome 
SCNT somatic cell nuclear transfer 
SOPs standard operation procedures 
SPF specific pathogen free 
TAH total artificial heart 
TALENs transcription activator-like effector nucleases 
TE trophectoderm 
THBD thrombomodulin 
TLA Targeted Locus Amplification 
TTS The Transplantation Society 
UDP-Gal uridine-diphosphate galactose 
UV ultraviolet 
WHO World Health Organization 
ZFNs zinc finger nucleases 
ABBREVIATIONS XVII 
 
 
TABLE OF CONTENTS XVIII 
 
 
 
Table Of Contents 
1 Introduction..................................................................................................................... 20 
2 Literature ......................................................................................................................... 22 
2.1 Introduction to xenotransplantation ............................................................................ 22 
2.1.1 Beginning of xenotransplantation.......................................................................... 22 
2.1.2 Transplantation of whole organs ........................................................................... 23 
2.1.3 Steps towards clinical trials ................................................................................... 25 
2.2 Safety aspects ............................................................................................................. 28 
2.2.1 Exogenous pathogens ........................................................................................... 28 
2.2.2 Endogenous pathogens......................................................................................... 34 
2.3 Requirements claimed by regulatory authorities .......................................................... 38 
2.3.1 World Health Organization (WHO)......................................................................... 38 
2.3.2 Food and Drug Administration (FDA) ..................................................................... 41 
2.3.3 European Medicines Agency (EMA) ....................................................................... 42 
2.3.4 Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) . 45 
2.3.5 Federation of European Laboratory Animal Science Associations (FELASA)............... 47 
3 Material and Methods .................................................................................................... 50 
3.1 PERV-C detection......................................................................................................... 50 
4 Results .............................................................................................................................. 60 
4.1 Population and raising up the xenotransplantation herd at CiMM ................................. 62 
4.2 Consistent success in life-supporting porcine cardiac xenotransplantation .................... 82 
4.3 Targeting αGal epitopes for multi-species embryo immunosurgery............................... 82 
4.4 Transmission of porcine circovirus 3 (PCV3) by xenotransplantation of pig hearts into 
baboons ................................................................................................................................. 83 
4.5 Inheritance of porcine endogenous proviruses in the xenotransplantation breeding herd 
at MABB................................................................................................................................. 84 
5 Discussion......................................................................................................................... 92 
5.1 Perspectives of xenotransplantation in comparison to alternatives ............................... 92 
5.2 The way towards an approved barrier facility for clinical trials ...................................... 95 
5.3 Novel pathogens to be considered for donor herd safety .............................................102 
5.4 Heredity of PERV-C proviruses in our xenotransplantation donor herd .........................104 
5.5 Anti-Gal antibodies – a vital heritage...........................................................................107 
TABLE OF CONTENTS XIX 
 
6 Summary ........................................................................................................................ 110 
7 Zusammenfassung ......................................................................................................... 112 
8 Literature........................................................................................................................ 114 
9 Figures ............................................................................................................................ 144 
10 Tables ............................................................................................................................. 146 
11 Appendix ........................................................................................................................ 148 
12 Acknowledgements ....................................................................................................... 158 
1 INTRODUCTION 20 
 
 
1 Introduction 
 
Cardiovascular diseases were the most common cause of death in the year 2017, since 37,0 % 
of all deaths in Germany were due to chronic ischemic heart disease and acute myocardial 
infarction (heart attack) (DESTATIS, 2019). The only cure for patients with cardiac end stage 
disease is heart transplantation, but the number of available human donor organs is anywhere 
near from the clinical need (LUND et al., 2017; EUROTRANSPLANT, 2018; 
ORGANTRANSPLANTATION, 2019). The demographic change and the advanced possibilities of 
modern society and medicine have led to an increase of elderly persons, who are even more 
susceptible to cardiovascular diseases. Moreover, not only the increase of elderly, but also the 
growth of diabetic and overweight people adds to the expanding demand for donor organs. 
Heart transplantation is not only performed in adults, but in pediatric patients, too, and the 
annual number of transplants has risen since the first transplant was performed in 1967 
(ROSSANO et al., 2017). Regarding pediatric transplants, infants (under 1 year of age) have 
accounted for the greatest number, with more than 1600 infant transplants reported from 
2004 to 2016 to the Registry of the International Society for Heart and Lung Transplantation 
(ISHLT). In infants, the most common diagnosis leading to transplantation was congenital 
heart disease (CHD). Usage of mechanical circulatory support (MCS) has continued as bridging 
to a transplant, with ventricular assist devices being the primary support modality. 
Nevertheless, in patients with CHD, especially among infants, the use of MCS was rarer. Only 
12% of infants with CHD were bridged to transplant on some form of MCS (ROSSANO et al., 
2017). The ongoing sensitization problem is an issue, in pediatric patients as well as in adult 
patients. 
Here, xenotransplantation can be an alternative to the classic bridge solutions, since when pig 
organs are used as bridge, there should be no occurrence of this phenomenon (overviewed in 
COOPER et al., 2004). After all, the rising demand for deceased donor organs urges a solution 
with we cannot offer from one day to another, but the very promising results in the field of 
xenotransplantation over the last years promise, that this may be a feasible and perceptible 
alternative to allotransplantation. First steps may be the usage of pig organs as bridges to 
transplants with lesser complications. If this succeeds, pig organs may replace whole human 
organs and not only serve as a bridge. There are plenty of possible applications for xenografts, 
e.g. the heart, the kidney, the cornea, the skin, the lung, the small intestine, and even the liver. 
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To reach this goal, we have to conduct clinical trials with the safest pig organs available. In 
order to establish a xenotransplantation donor herd, which fits the strict requirements 
demanded by regulatory authorities and experts in the various fields of the 
xenotransplantation context, a hygiene management was established in our 
xenotransplantation donor herd as a first step towards safe pig organs, a clean and pathogen 
free herd, to provide safe donor pigs and therefore paving the way towards clinical 
xenotransplantation trials. 
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2 Literature 
 
2.1 Introduction to xenotransplantation 
 
2.1.1  Beginning of xenotransplantation 
 
The idea of xenotransplantation, the transplantation of organs, tissue and cells between 
phylogenetically different species is not new. The very first blood transfusion between a 
human being, who suffered from severe fever, and a lamb took place in 1667 in Paris 
(reviewed in ROUX et al., 2007). The French physician Jean-Baptiste Denis performed several 
such xenotransfusions, but the procedure was prohibited, when one of the patients died 
(reviewed in DESCHAMPS et al., 2005; reviewed in ROUX et al., 2007). 
The next step towards xenotransplantation to humans was the transplantation of skin in the 
19th century. There were two different techniques for skin transplantation, free grafts and 
pedicled grafts. In the latter case, grafts were only partially detached from the donor and 
applied to the recipient. During engraftment donor and recipient had to be fixed together until 
the graft was fully vascularized on the recipient’s transplantation site (GIBSON, 1955; COOPER, 
1997). The fact that many donor species had appendages on the skin, e.g. feathers, wool or 
fur led to the use of frogs as preferred donors (GIBSON, 1955; reviewed in MOU et al.,  2015). 
Another significant development was the first corneal xenotransplantation performed by 
Richard Sharp Kissam in 1838 from pig to human. This experiment was followed by various 
attempts which involved alternative donor species like dog, sheep and cows, whereas the first 
corneal allotransplantation took place only about half a century later in 1905 (reviewed in 
HARA & COOPER, 2010; reviewed in COOPER et al., 2015). 
A major step forward towards transplantation of whole organs was the development of blood 
vessel anastomosis by Nobelprize winner Alexis Carrel in 1912 (reviewed in DESCHAMPS et al., 
2005; reviewed in MOU et al., 2015). A student of Alexis Carrel, Serge Voronoff, was a pioneer 
in endocrinotherapy. He transplanted slices of chimpanzees’ testicles into the human 
recipient’s scrotum in June 1920. Voronoff aimed for a “rejuvenation” by his surgical 
procedure (AUGIER et al., 1996). Remarkably, Voronoff was also the first person who struggled 
with the limited availability of apes, which he overcame by building so-called ape houses in 
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French Guinea to rear apes for exporting (reviewed in DESCHAMPS et al., 2005; reviewed in 
ARISTIZABAL et al., 2017). Since then primates were inevitable for xenotransplantation, either 
as donors or as recipients in preclinical studies. 
 
2.1.2  Transplantation of whole organs 
 
In the 2nd half of the 20th century replacement of organs became a valuable treatment of 
patients suffering from end stage organ failure. Initially, pioneers in the field followed both, 
allo- as well as xenotransplantation approaches. 
Using the anastomosing technique introduced by Carrel, the kidney was the first solid organ 
to be xenotransplanted, because it is a paired organ, it is vascularized by one single artery and 
its function is proven by urine production (reviewed in DESCHAMPS et al., 2005). From 1963 
to 1964, Keith Reemtsma performed 13 chimpanzee to human kidney xenotransplantations. 
There, an immunosuppression regimen with azathioprine, actinomycin C, steroids and x- 
radiation was included for the first time. However, none of the patients lived longer than 4-8 
weeks. Only a 23-year old woman remained at good health for up to nine months until she 
suddenly collapsed and died (REEMTSMA et al., 1964). 
About 30 years after Reemtsma’s kidney xenotransplantations, in June 1992, Tom Starzl and 
his team did a baboon to human liver transplantation, with the 35-year old male recipient 
surviving for 70 days (STARZL et al., 1993). 
Nearly at the same time as Reemtsma, James Hardy, performed not only the first human lung 
allotransplant, but was also drawn to carry out the first clinical heart allotransplantation. As 
his patient was in dreadful and semi-comatose state and no allograft was available, Hardy 
transplanted a chimpanzee heart (HARDY et al., 1963; HARDY et al., 1964). The contradictory 
response to this heart xenotransplantation however discouraged Hardy from further tries. 
Only four years later the first successful cardiac allotransplantation was famously introduced 
in 1967 in Cape Town by Christiaan Barnard and his colleagues (BARNARD, 1967). Barnard also 
aimed at the usage of xenografts for the heterotopic cardiac xenotransplantations. He 
performed two, one with a baboon heart and one with a chimpanzee’s heart, mainly due to 
shortage of human donor organs (BARNARD et al., 1977). 
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Barnard’s work was followed by another famous clinical cardiac xenotransplantation in 1983. 
Leonard Bailey carried out the first cardiac xenotransplantation in a neonate, “Baby Fae”. She 
suffered from hypoplastic left heart syndrome, received a baboon heart and survived for 20 
days, as the graft experienced acute rejection (BAILEY et al., 1985; reviewed in MOU et al., 
2015). Additionally, the graft was ABO-incompatible, because the blood-type O is rarely seen 
in baboons (DIAMOND et al., 1997). Even the innovative and highly potent 
immunosuppressive agent cyclosporine could not prevent cross -species rejection (reviewed 
in MURTHY et al., 2016). Eventually, allotransplantation of human organs became clinic 
routine, while xenotransplantation remained a research objective. Nonetheless, the interest 
in xenotransplantation remained. The main reasons are the predicted extended availability of 
donors and the proposed planning of transplantations. Importantly, the role of nonhuman 
primates changed from donors to recipients in preclinical studies and the pig, especially if 
genetically modified, became the preferred organ source (WEISS, 2018). The main reasons are 
the lower ethical concerns, well-established housing conditions and their high reproductive 
capacity. 
The latter is highly relevant, as we are still battling shortage of deceased organ donors. In 
Germany for example, in 2018, 955 donors provided 3.113 organs, in contrast to 9.697 organs 
in demand (ORGANTRANSPLANTATION, 2019). For hearts we are facing a gap between 295 
donated organs and 719 required hearts (ORGANTRANSPLANTATION, 2019). Within the 
Eurotransplant member states there were 619 hearts from deceased donors used, but still at 
the end of 2018 there were 1158 people on the active waiting lists (EUROTRANSPLANT, 2018). 
Alternative mechanical circulatory assist devices have greatly improved with new design and 
better patient survival (KIRKLIN et al., 2013; KIRKLIN et al., 2015). However, the main 
limitations of the mechanical assist devices are gastrointestinal bleeding, followed by heart 
failure and arrhythmia, infections, thrombosis and power supply limitation (HASIN et al., 2013; 
PATEL et al., 2014). 
Furthermore, more patients would profit from a donor organ and they would profit from it at 
an earlier timepoint, if only there was greater availability (MOHIUDDIN et al., 2015). Before 
clinical application of xenotransplantation is realistic, however, solid and convincing 
preclinical pig-to-nonhuman primate studies are necessary. 
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2.1.3  Steps towards clinical trials 
 
The first hurdle to overcome in pig-to-nonhuman primate cardiac xenotransplantation (CXTx) 
was hyperacute xenograft rejection (HAR), which is a complement mediated vascular injury 
caused by pre-formed antibodies in the recipient against galactose α-1,3galactose (αGal) 
epitopes on the endothelium of the graft (BUHLER et al., 1999) (reviewed in YANG & SYKES, 
2007). These epitopes are synthetized by the enzyme α-1,3-galactoseyltransferase, encoded 
by GGTA1, which is functional in most of the species, including pigs, but not in Old World 
monkeys, apes and man (GALILI et al., 1988b; GALILI, 1993). Therefore, these species produce 
naturally anti- αGal antibodies, since they are exposed to αGal epitopes from gastrointestinal 
bacteria (GALILI et al., 1988a). The first idea to overcome HAR was to develop pigs expressing 
human complement regulatory proteins (MCCURRY et al., 1995; MCCURRY et al., 1996), like 
the membrane cofactor protein CD46 (DIAMOND et al., 2001) (hCD46), the membrane 
inhibitor of reactive lysis CD59 (DIAMOND et al., 1996) (hCD59) and the decay acceleration 
factor CD55 (LANGFORD et al., 1994) (hCD55). Additionally, pigs with various combinations  of 
these genetic modifications were established (BYRNE et al., 1997; COWAN et al., 2000; 
RAMSOONDAR et al., 2003). 
Rejection time of xenografts from pigs transgenic for human complement regulatory proteins 
varied from one week to three weeks, depending on whether immunosuppression agents 
were used or not (GODDARD et al., 2002; EKSER et al., 2009). Alternative approaches such as 
blocking the anti-Gal antibodies by in vivo removal (TANIGUCHI et al., 1996), intravenous 
infusion with carbohydrates (YE et al., 1994), conjugation of polyethylene glycol to αGal- 
oligosaccharides in order to achieve a prolonged action of inhibitors were tested (NAGASAKA 
et al., 1997). In addition, other glycoconjugates and combinations of them were compared to 
their ability to block anti-Gal antibody binding (BYRNE et al., 2002). Longest survival, with 139 
days, was achieved by administering immunosuppression with e.g. mycophenolate mofetil, 
methylprednisolone, cobra venom factor and anti-CD154 mAbs on top of continuous 
intravenous infusion with αGal glycoconjugates (KUWAKI et al., 2004). 
The ultimate solution for overcoming HAR, however, required the removal of the preformed 
antibody target, the αGal epitope. In 2002, the first four live heterozygous α-1,3-GGTA1 knock- 
out pigs were produced by somatic cell nuclear transfer (DAI et al., 2002; LAI et al., 2002) and 
shortly after, the production of homozygous GGTA1 knock-out (GTKO) pigs was reported in 
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2003 (PHELPS et al., 2003). The first promising results using these pigs as donors were 
published in 2005, with maximum graft survival of 179 days (median of 78 days) (KUWAKI et 
al., 2005). However, xenotransplantation experiments carried out by other groups showed 
varying survival times (AZIMZADEH et al., 2015), probably related to differences in the 
immunosuppression regimens (AZIMZADEH et al., 2015), the health status of the recipient as 
well as of the donor (MOHIUDDIN et al., 2012; HIGGINBOTHAM et al., 2015), or the infection 
status of certain pathogens, e.g. porcine cytomegalovirus (YAMADA et al., 2014). 
Another antibody mediated process, which had to be overcome is acute humoral xenograft 
rejection (AHXR) (reviewed in KLYMIUK et al., 2010). AHXR is also known as “acute vascular 
rejection” or “delayed xenograft rejection”, but AHXR reflects most closely the presumed 
pathogenesis of an antibody-mediated rejection, with likely involvement of complement 
(reviewed in SCHUURMAN et al., 2003). It appears that AHXR cannot be completely avoided, 
even if animals receive continuous treatment and even if the donor organ is from an animal 
transgenic for a human complement regulatory protein (reviewed in SCHUURMAN et al., 
2003). The multifactorial aspects of AHXR like endothelial cell activation and injury, destroying 
the anticoagulant features of the endothelium and so leading to thrombotic microangiopathy 
and disseminated intravascular coagulopathy are also reflected in histopathologic features. 
The best documented case is the description of AHXR in a pig-to-nonhuman primate kidney 
xenotransplantation model, where the histology fully resembled glomerular thrombotic 
microangiopathy (SHIMIZU et al., 2000). Several strategies to improve graft survival were 
discussed, like transgenic pigs for human ecto-ADPase (CD39), human thrombomodulin 
(THBD), endothelial protein C receptor (EPCR), heme oxygenase 1 and tissue factor pathway 
inhibitor (TFPI) (reviewed in D'APICE & COWAN, 2009). But the best success was achieved by 
pigs expressing human THBD gene (hTBM) under the control of the porcine THBD promoter, 
to overcome the impaired activation of protein C on the porcine endothelium (WUENSCH et 
al., 2014). Such pigs were generated in 2014 at our institute, on the background of a GGTA1 
knock-out (PHELPS et al., 2003) and human CD46 transgenic (LOVELAND et al., 2004) (hCD46) 
pig, according to our established work flows (KUROME et al., 2006; KLYMIUK et al., 2012b; 
RICHTER et al., 2012; KUROME et al., 2013; KUROME et al., 2015) (reviewed in AIGNER et al., 
2010b; reviewed in AIGNER et al., 2010a; reviewed in KLYMIUK et al., 2010). In vitro studies 
from different groups show beneficial effects of cells from pigs expressing hTBM (WUENSCH 
et al., 2014; BONGONI et al., 2016; BONGONI et al., 2017). 
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The beneficial effect of hTBM transgene expression can also be seen in few heterotopic 
cardiac xenotransplantation (hCXTx) studies, using hTBM transgenic pigs (ABICHT et al., 2015). 
Here, donor hearts transgenic for hTBM showed undoubtedly the best graft survival, with 
minimal thrombocytopenia and bleeding, compared to anti-CD154 treated recipients 
(MOHIUDDIN et al., 2014; MOHIUDDIN et al., 2016). Additionally to the findings, a very recent 
study compared the survival of grafts from pigs transgenic for GTKO.hCD46.hTBM 
(MOHIUDDIN et al., 2016) to those only transgenic for GTKO.hCD46 (SINGH et al., 2019), with 
the conclusion that all grafts show reduced survival in the absence of THBD transgene 
expression. 
As the median survival time in hCXTx is now 298 days long (minimum 159 days to maximum 
945 days) (MOHIUDDIN et al., 2016), it is more than 2-fold longer than recommended by the 
ISHLT committee on Xenotransplantation for the duration of life-supporting preclinical studies 
(COOPER et al., 2000). The next logical step was to bring orthotopic cardiac 
xenotransplantation (oCXTx) to the same level of survival time. But this procedure is far more 
complex and critical to perform, so there have been relatively few live supporting oCXTs 
studies (SCHMOECKEL et al., 1998; WATERWORTH et al., 1998; XU et al., 1998; VIAL et al., 
2000; BRANDL et al., 2005; BRANDL et al., 2007; MCGREGOR et al., 2008; MCGREGOR et al., 
2009). These studies used GTKO.hCD46 transgenic pigs or pigs only transgenic for human 
complement regulatory proteins, with and without αGal-oligosaccharides to block anti-Gal 
antibodies. 
Xenograft survival in oCXTx studies ranged from 1 to 57 days and in most cases the recipient 
died because of postoperative complications rather than graft rejection. Although the grafts 
showed limited histological signs of rejection, gene expression analysis revealed that the 
hearts were exposed to ongoing immune challenge and endothelial cell activation (BYRNE et 
al., 2011). These earlier studies, which did not employ the latest immunosuppression regimens 
from the hCXTx studies indicated, that oCXTx is not limited by cardiac function, but by 
challenges of immune rejection and postoperative management (MOHIUDDIN et al., 2015). 
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2.2 Safety aspects 
 
2.2.1  Exogenous pathogens 
 
As post-transplantation infections are commonly seen as side effects in allotransplantations, 
they might occur in any immunocompromised transplant recipient. The risk of infections is 
based on the interaction of the immune system of the recipient and the virulence, dose and 
intensity of specific organisms that are present in the donor graft (reviewed in FISHMAN, 
2018). 
In allotransplantation, the prevention of donor-derived infections is achieved by donor 
screening and selection (NELLORE & FISHMAN, 2018). There are multiple existing guidelines 
for screening, but the time within which organs may be used is limited and so is 
microbiological screening from either serologies or nucleic acid tests. Furthermore, the data 
from samples taken for culture are only available after transplantation and therefore only an 
advice for choosing the fitting antimicrobial treatment of the recipients. Screening criteria may 
be adapted, respecting the geographic region, travelling history of donor and recipient, local 
microbiologic epidemiology or individual donor exposures, for example Chikungunya virus 
(DALLA GASPERINA et al., 2015; PIERELLI et al., 2018), West Nile virus (RAZONABLE, 2016; 
VELATI et al., 2017) or the severe acute respiratory syndrome (SARS). Sudden clusters of 
infections among recipients sharing a common donor, or when recipients develop a disease 
for which they had no exposure, may lead to the conclusion of donor-derived infections. 
Recent cases of dengue virus (GUPTA et al., 2016), hepatitis C virus (HCV) (ANONYMUS, 2011), 
and human immunodeficiency virus (HIV) (ANONYMUS, 2011) have shown, not only deceased 
organ donors pose a risk for such infections, but also living organ donors. Regardless of all the 
limitations, unexpected donor-derived infections are estimated to occur in 0,2% of solid organ 
transplant recipients (WOLFE et al., 2019) (reviewed in ISON & NALESNIK, 2011). 
With clinical xenotransplantation studies being more and more within the grasp of 
researchers, the demand for safe and nonhazardous donor pigs has, thus, become a widely 
discussed topic. These zoonotic infections, in the xenotransplantation context called 
“xenozoonosis” or “xenosis” to underline the unique epidemiology, comprise known as well 
as unknown pathogens. Therefore, the goal of pig husbandry for xenotransplantation is to 
exclude potential pathogens and to obviate the introduction of any new safety risks, as for 
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many pig pathogens the potential to cross the species barrier to humans in an 
immunocompromised patient is not known and for many pathogens microbiological assays 
have not yet been developed. 
But once validated, these assays can be run on a herd or on single donor animals. In contrast 
to deceased human donor organs, pigs can be screened on a routine basis and even more 
intensive. Eventually, screening schemes might be created to exclude organisms of risk to 
human transplant recipients, which allows the selection of swine, free of selected potential 
pathogens, termed “designated pathogen free” (DPF) (FISHMAN, 1997, 1998, 2001) (reviewed 
in FISHMAN & PATIENCE, 2004). Some pig pathogens have known zoonotic potential and are 
known to infect both, human and swine, like hepatitis E virus and influenza virus, many 
bacteria, like Salmonella species, Pasteurella species, Pseudomonas species, Yersinia species, 
Campylobacter species and Listeria monocytogenes and fungi, like Aspergillus species and 
Candida species. Bacterial and viral infections predominate the scientific literature in the risk 
analysis, though parasites are increasingly being recognized for their potential to influence on 
the outcome of a transplantation (FABIANI et al., 2018; LA HOZ & MORRIS, 2019). 
Toxoplasmosis, for example may be the most prevalent infection in human, with an estimated 
30-50% of the world’s population previously exposed (FLEGR et al., 2014). Toxoplasmosis is 
caused by a protozoan, called Toxoplasma gondii and infection can be foodborne, zoonotic, 
congenital, from blood transfusion or organ transplants from infected donors (Center for 
Disease Control, CDC). Screening of all organ donors, not only for allo- but also for 
xenotransplantation, and recipients is recommended. The most frequent transmission occurs 
in seronegative recipients from a heart of a Toxoplasma IgG-positive donor, unless they 
receive prophylaxis (LUFT et al., 1983; WREGHITT et al., 1989). 
Chagas, an infection with the protozoan parasite Trypanosoma cruzi, which is transmitted to 
humans by reduviid bugs of the subfamily Triatominae, causes one of the world’s most 
neglected tropical diseases, as listed by the World Health Organization (WHO) (COMMITTEE, 
2002; HOTEZ et al., 2007; LA HOZ & MORRIS, 2019). After feeding on the host, these blood- 
sucking insects release infectious trypomastigotes in their feces, which enter the host through 
the wound, conjunctiva or adjacent mucosa. But infection can also occur through vertical 
transmission, oral ingestion of contaminated food or water, as well as blood transfusion or 
organ transplantation (reviewed in BERN et al., 2007; RASSI et al., 2010). Considerations on 
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screening recipients and donors, should be taken, because of the overall epidemiologic shifts 
of diseases, as well as more and more people travelling to foreign countries and with more 
immigrants of foreign countries becoming possible organ donors in developed countries, thus 
bringing unknown diseases and pathogens with them. 
Babesia, another species of protozoan parasites, are transmitted through tick vectors. They 
are common in most domestic animals (overviewed in UILENBERG, 2006), as well as in 
humans. Healthy people may clear the infection without treatment, but the resolution of the 
infection depends on the innate and adaptive immune system. Therefore, infection with 
Babesia is more severe in persons under immunosuppression, asplenic patients or those 
infected with certain species (VANNIER & KRAUSE, 2012). 
Porcine cytomegalovirus (PCMV), a β- herpesvirus related to the human cytomegalovirus is 
acquired by piglets very early in life and leads to a lifelong seroconversion and latent viral 
infection (reviewed in MUELLER & FISHMAN, 2004). PCMV causes systemic disease and 
eventually leads to transplant failure of xenografts in preclinical studies (YAMADA et al., 2014), 
like human cytomegalovirus in allotransplantation. Whether PCMV can infect human cells is 
adversely discussed, with two studies showing on the one hand, possible in vitro infection 
(WHITTEKER et al., 2008) and the other study showing no evidence for this (TUCKER et al., 
1999). Available antiviral therapy, for example cidofovir and foscarnet may have therapeutic 
effect on PCMV viral load in achievable concentrations, but in these concentrations these 
agents often carry significant toxicity for the transplant recipients (MUELLER et al., 2003). 
Ganciclovir failed to prevent PCMV infection in various pig-to-baboon solid organ 
xenotransplantation models. The lack of therapeutic agents makes the establishment of PCMV 
free swine herd of utmost importance for xenotransplantation. 
Hepatitis E virus (HEV) is the main course of acute viral hepatitis worldwide (reviewed in 
CLEMENTE-CASARES et al., 2016). It is a pathogen of both, humans and swine and often 
associated with contaminated food or water. It is estimated that one-third of the world 
population has been exposed to the agent (REIN et al., 2012). Pigs, wild boars and deer are 
the reservoirs of HEV genotype 3 and 4 (reviewed in KHUROO & KHUROO, 2016). Most human 
infections occur through intake of undercooked or uncooked meat of infected species, like 
domestic pigs, especially pig liver and liver products. But also human to human transmission 
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is possible, through infected blood transfusions and blood component transfusions. Donor 
screening for HEV in allotransplantation is under serious consideration. 
Considering all the pathogens described here and all the potentially hazardous but yet 
unknown pathogens, the basis of producing donors for xenotransplantation will always be 
good veterinary practice, good laboratory practice and good manufacturing practice. Pigs 
might be bred under special conditions, in so-called biosecure environments, with hygiene 
sluices adapted to the level of biosecurity. The employees and caretakers have to be trained 
to follow certain steps when entering the housing, maybe showering with full cloth change 
afterwards, going through air sluices even in the housing, from the highest hygiene level to 
the lowest. Some authors suggest the use of routine vaccines (GAZDA et al., 2016) and a more 
or less wide screening program to achieve microbiological safety for clinical trials 
(GARKAVENKO et al., 2004a; GARKAVENKO et al., 2008a; WYNYARD et al., 2014; SPIZZO et al., 
2016; FISHMAN, 2018). 
 
 
Following, Table 1 shows a summary of important publications regarding screening concepts 
for pig herds bred for xenotransplantation. 
 
 
Fishman 
2018 
Spizzio 2016 
(IXA) 
Wynyard 
2014 
New Zealand 
Garkavenko 
2004a+2008a 
Bacteria     
Leptospira 
Serovar Tarrasovi 
  
 
Leptospira 
Serovar Hardjo 
  
 
Leptospira 
Serovar Pomona 
  
 
Mycoplasma 
hyopneumoniae 
  
 
Campylobacter 
  
 
Yersinia     
E.coli K88     
Salmonella spp.     
Mycobacterium 
tuberculosis 

   
Shigella     
nontuberculous 
mycobacteria 

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+ M.bovis     
Listeria 
monocytogenes 

   
Brucella suis     
     
Viruses     
MRV     
HERV-K     
PCV1     
PCV2    
PLHV    
PLHV2     
PCMV    
Rotavirus A-C     
Reovirus     
PTV     
PEVB     
PHEV     
HEV     
BVD     
SuHV-1 (AujD)     
PPV     
PRRSV     
EMCV     
PERV    
Adenovirus     
Rabies virus     
Influenza virus 
(human) 

   
Influenza virus 
(swine) 

   
     
Protozoa/ 
Parasites 
    
Toxoplasma 
gondii 
  
 
Ascaris suum     
Cryptosporidium/ 
Microsporidium 
spp. 
 

 

 

 
Echinococcus 
spp. 

   
Giardia spp.     
Isospora sp.     
Strongyloides sp.     
Trichinella 
spiralis 

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Trypanosoma 
spp. 

   
     
Fungi     
Aspergillus sp.     
Candida sp.     
Cryptococcus 
neoformans 

   
Histoplasma 
capsulatum 

   
 
 
Table 1 Pathogens that should be excluded from a designated pathogen free pig herd for 
xenotransplantation, adapted from references (GARKAVENKO et al., 2004a; GARKAVENKO et 
al., 2008a; WYNYARD et al., 2014; SPIZZO et al., 2016; FISHMAN, 2018). 
(MRV: mammalian orthoreovirus, HERV-K: Human endogenous retrovirus K, PCV1 /2: porcine circovirus 1/2, 
PLHV: porcine lymphotropic herpesvirus, PLHV2: porcine lymphotropic herpesvirus 2, PCMV: porcine 
cytomegalovirus, PTV: porcine teschovirus, PEVB: porcine enterovirus, PHEV: porcine hemagglutinating 
encephalomyelitis virus, HEV: hepatitis E virus, BVD: bovine virus diarrhea, SuHV-1 /AujD: suid alphaherpesvirus 
1/ Aujezsky’s disease, PPV: porcine parvovirus, PRRSV: porcine reproductive and respiratory syndrome virus, 
EMCV: encephalomyocarditis virus, PERV: porcine endogenous retrovirus) 
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2.2.2  Endogenous pathogens 
 
Discussing safety aspects, not only the exogenous pathogens are to consider, but also the 
endogenous pathogens, above all, the porcine endogenous retroviruses (PERVs). Considering  
that the human acquired immune deficiency syndrome (AIDS) viruses were zoonotic 
transmission of primate lentiviruses, the transmission characteristics of PERVs have to be 
studied very carefully (SHARP PAUL et al., 1995; GAO et al., 1999). 
According to the current classification of the International Committee on Taxonomy of Viruses 
(ICTV) PERVs belong the Retroviridae family, subfamily of Orthoretrovirinae, the genus 
Gammaretrovirus and the species Porcine type – C oncovirus (ICTV, 2019). 
Resembling virus-like particles as those seen in baby hamster kidney cell line (BHK-21) and 
murine cells infected with murine leukemia virus (MLV) PERVs were first described in 1970 
(BREESE, 1970). They are close related to MLV, feline leukemia virus (FeLV), gibbon ape 
leukemia virus (GaLV) and koala retrovirus (KoRV) (reviewed in DENNER, 2007; reviewed in 
DENNER, 2008a). Sequences similar to mouse endogenous retroviruses indicate that PERVs 
originated from mouse endogenous retroviruses about 7.4-8.3 million years ago, which 
correlates with the point of separation between pigs and peccaries (TONJES & NIEBERT, 2003; 
NIEBERT & TONJES, 2005; TANG et al., 2016). Recent scientific findings reveal, that 
retroviruses themselves are much more older, have ancient marine roots and originated over 
450 million years ago in the early Palaeozoic Era (AIEWSAKUN & KATZOURAKIS, 2017). 
PERVs are characterized by the possession of the enzyme reverse transcriptase (RT) (reviewed 
in LOPATA et al., 2018). RT transcribes genomic ribonucleic acid (RNA) into double stranded 
deoxyribonucleic acid (DNA). This double stranded DNA, which is then called the provirus, 
integrates itself unperceived into the host’s genome. This also affects the germ line of the 
host, which gives the provirus the possibility to be passed from one generation to another, 
thus becoming an endogenous retrovirus (ERV) (HAYWARD & KATZOURAKIS, 2015; 
HAYWARD, 2017) (reviewed in WEISS, 2006). The once into the germline integrated provirus 
is inherited as retroviral insertion to the host’s descendants following the Mendelian rules, 
which characterizes ERVs. 
This presents us with the challenge that PERVs cannot be eliminated by the standard hygiene 
measurements and methods, like cleaning, disinfection or air filtration but other methods  
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than currently employed in barrier facilities to exclude exogenous pathogens (SCHUURMAN, 
2009) (reviewed in SCOBIE & TAKEUCHI, 2009). 
With porcine kidney cell lines spontaneously producing C-type retrovirus particles 
(ARMSTRONG et al., 1971), the question if they can infect human cells arose (PATIENCE et al., 
1997). Followingly, the three replication-competent subfamilies PERV-A, PERV-B and PERV-C 
were identified (TAKEUCHI et al., 1998). The two subfamilies PERV-A and PERV-B were found 
of being capable to infect human cells in vitro (LE TISSIER et al., 1997). These two human-tropic 
PERVs can be found in all pigs (DENNER & SCOBIE, 2019). PERV-C on the other hand, is not 
ubiquitous in the pig population and can only infect pig cells. 
As it is not yet sure, if PERVs can infect human cells in vivo, they have to be seen as a thread 
to xenotransplant recipients, especially, as mentioned above, that it was shown, that PERVs 
can infect human cells in vitro (LE TISSIER et al., 1997; PATIENCE et al., 1997; TAKEUCHI et al., 
1998; SCOBIE & TAKEUCHI, 2009). But still it has to be kept in mind, that the envelop (env) 
gene determines the viral tropism, consequently the virus receptor (TAKEUCHI et al., 1998; 
LEE et al., 2006) and so far, only the receptor for PERV-A has been identified (reviewed in 
LOPATA et al., 2018). In pigs it is called porcine PERV-A receptor (PoPAR), in baboons, baboon 
PERV-A receptor 2 (BaPAR-2) and in humans are two known receptors, human PERV-A 
receptor 1 (HuPAR-1) and human PERV-A receptor 2 (HuPAR-2) (ERICSSON et al., 2003). 
HuPAR-1 expression is more widespread (YONEZAWA et al., 2008; MARCUCCI et al., 2009; YAO 
et al., 2010), but it is peculiarly enhanced in the brain and the salivary glands (NAKAYA et al., 
2011). Contradictory, the expression of HuPAR-2 is elevated in the placenta and the small 
intestine. Although expression of these receptors is nearly ubiquitous in most human tissues 
examined in the study by Ericsson et al., other in vitro studies have shown, that only few 
human and nonhuman primate cells were permissive for productive PERV-A infection, even if 
they were susceptible for PERV-A entry (WILSON et al., 2000; RITZHAUPT et al., 2002). It was 
shown that HuPAR-2 is on average 11-fold more functional than HuPAR-1 regarding PERV-A 
infection and this increase in infectivity was no matter of any difference in viral envelope 
binding, but in fact is due to the inherent biological variability of viral infection testing 
strategies (MARCUCCI et al., 2009). PERV transmission has been confirmed to human 
peripheral blood mononuclear cells (PBMCs) (CLEMENCEAU et al., 2001; SPECKE et al., 2001), 
primary endothelial cells and primary aortic smooth muscle cells (SPECKE et al., 2001), 
vascular fibroblasts and mesangial cells (MARTIN et al., 2000), human embryonic kidney (HEK) 
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293 cells (MARTIN et al., 1998; LEE et al., 2008) and normal dermal human fibroblasts (NHDFs) 
(KIMSA et al., 2013). Nonetheless, in vivo, PERV transmission has never been observed among 
patients after pancreatic islets xenografts (HENEINE et al., 1998; GARKAVENKO et al., 2004b; 
VALDES-GONZALEZ et al., 2010; MOROZOV et al., 2017), patients upon receipt of fetal porcine 
neuronal cells (FINK et al., 2000), recipients of porcine liver cell -based bioartificial liver (DI 
NICUOLO et al., 2005; DI NICUOLO et al., 2010), porcine skin graft recipients (SCOBIE et al., 
2013) and lastly butchers, who are on a daily basis in close contact with pig tissue (PARADIS et 
al., 1999; DENNER, 2008b; DENNER & TONJES, 2012). Therefore, it still is questionable if the 
human cells used in in vitro studies, for example the widely used HEK293 cells are 
representative, because of different virus receptors and different levels of expression in 
different tissues, which too, are very likely to be influenced by various factors, like dependency 
networks, that cannot be mimicked in cell culture in exact the same way as it is in a living 
organism. 
Recently, studies with inbred miniature swine and melanoma-bearing pigs described a human- 
tropic, replication competent, recombinant, high-titer PERV-A/C, which de novo integrated 
into the genome of the spleens of the pigs, but was not found in the germ line (BARTOSCH et 
al., 2004; WOOD et al., 2004; MARTIN et al., 2006; DIECKHOFF et al., 2007; DENNER, 2008c; 
KARLAS et al., 2010). PERV-A/C was transmitted to human cells in vitro, with the receptor 
binding domain of PERV-A combined with PERV-C related sequences (OLDMIXON et al., 2002; 
BARTOSCH et al., 2004). Most of the studies used PBMCs derived from miniature pigs, to 
demonstrate the transmission of recombinant PERV-A/C. These experiments have been 
repeated with PBMCs from the Auckland Islands pigs of New Zealand with the result, that no 
PERV was transmitted, either to human or to pig cells (GARKAVENKO et al., 2008c; 
GARKAVENKO et al., 2008b). In a preclinical pig-to-primate islet cell xenotransplantation study 
drawn out in 2008, where also cells from the Auckland Islands pigs were used, there was no 
evidence of virus transmission to the nonhuman primates (GARKAVENKO et al., 2008a). To 
simulate the situation after a possible xenotransplantation to humans in vitro, serial cell-free 
passages were performed on human cells, which resulted in the increase of the titer of the 
virus (WILSON et al., 2000; DENNER et al., 2003). This increase was associated with genetic 
changes in the viral long terminal repeats (LTR), which was similar when PERV-A was passaged 
(WILSON et al., 2000; SCHEEF et al., 2001). But when compared with the paternal PERV-A, 
mutations in the env gene were identified, that also might be responsible for high titers 
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(HARRISON et al., 2004). Furthermore, shows PERV-A/C an enhanced RT activity compared to 
PERV-A (WOOD et al., 2009). To avoid the assembly of recombinant, high-titer PERV-A/C it is 
strongly recommended to avoid pig strains carrying ecotropic PERV-C for breeding animals for 
xenotransplantation (DENNER et al., 2009). 
Several efforts to minimizes the risk of PERV transmission have been made, but all only had 
limited success. To increase viral safety by RNA interference, transgenic pigs expressing a 
PERV-specific small hairpin RNA were generated, in which expression of PERVs was  reduced 
(DIECKHOFF et al., 2008; RAMSOONDAR et al., 2009; SEMAAN et al., 2012). Another attempt 
was the design of vaccines (FIEBIG et al., 2003; KAULITZ et al., 2011) or the use of antiretroviral 
drugs (such as azidothymidine) (QARI et al., 2001; STEPHAN et al., 2001; SHI et al., 2007) 
(reviewed in DENNER, 2017) and PERV elimination by using zinc finger nucleases (SEMAAN et 
al., 2015) (ZFNs) and transcription activator-like effector nucleases (DUNN et al., 2015) 
(TALENs). 
A successful inactivation of all 62 copies of the PERV pol gene in the PK15 cell line (YANG et 
al., 2015) was achieved by usage of the RNA-guided clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR-associated (Cas) system (JINEK et al., 2012; CONG et al., 
2013; MALI et al., 2013). With this approach it was possible to effect a 1000-fold reduction of 
infectivity of PERV of human cells (YANG et al., 2015), which demonstrates, that PERVs can be 
inactivated in pig genomes for clinical application of pig-to-human xenotransplantation. With 
only little adaption, this technique was used to produce 37 PERV-inactivated piglets by somatic 
cell nuclear transfer (SCNT), from which 15 piglets remained alive to conduct long term studies 
to monitor the impact of PERV-inactivation and gene editing on animals (NIU et al., 2017). 
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2.3 Requirements claimed by regulatory authorities 
 
2.3.1  World Health Organization (WHO) 
 
In the documentation center on the WHO website, there are several guides, 
recommendations and regulations available, dealing with xenotransplantation and different 
topics regarding xenotransplantation. 
The “Guide on Infectious Disease Prevention and Management” from 1998 deals with the 
requirements for xenotransplantation (WHO, 1998). It discusses the possible dangers of 
introducing animal-origin infectious agents into human population and how to best avoid 
these and related dangers. It guides the reader through the process of developing a 
xenotransplantation infectious agent exclusion list and designing a surveillance program. 
First, the risk of exposure, the potential for introducing the infectious agent into the recipient, 
must be recognized and assessed. If a risk of exposure is given, the potential for establishment 
in the new host must be then considered and evaluated: Does the establishment only require 
direct contact or is adaption or genetic alteration required? Is the establishment restricted to 
the transplanted tissue or is there a possibility to disseminate throughout the new host? If this 
could be the case, the likelihood of disease production in the general population must be 
assessed (WHO, 1998). 
In Annex I a list is attached with suggested criteria for consideration when developing a 
xenotransplantation infectious-agent exclusion list. But any list must be drafted with 
professional judgement and cautious flexibility, to assure the list reflects the best possible 
integration of technical feasibility and risk acceptability. These two factors will, to a large 
extent, dictate the number and type of agents in the xenotransplantation context (WHO, 
1998). Further, should the list be generated by a consortium of experts representing all 
scientific fields involved in xenotransplantation. Periodic reviews and updates of the list 
should be out of question. Obviously, the generation of the specific agent exclusion list will be 
or is, an enormous but necessary task (WHO, 1998). 
The “Guide on Infectious Disease Prevention and Management” also discusses how to 
minimize the risk to public health, which includes, among others, the establishment and 
implementation of stringent selection requirements for prospective tissue and organ donor- 
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animals (WHO, 1998). This implies the maintenance, licensing of xeno-dedicated animal 
colonies, which are closely monitored in a surveillance program. 
To give the best possible infectious disease prevention, in the case of xenotransplantation, the 
surveillance program should not be restricted to be donor animals, but also a practical and 
clinically feasible recipient follow-up must be designed, to detect and contain unrecognized 
or emerging infectious agents (WHO, 1998). 
The “OECD/WHO Consultation on Xenotransplantation Surveillance: Summary Report” from 
2001 (WHO, 2001b) summarizes the topics, issues and considerations discussed at the 
OECD/WHO Consultation on Xenotransplantation Surveillance held in Paris on 4-6 October 
2000. The purpose was to bring together epidemiologists, infectious disease specialists, 
clinicians, industry, government and international organization representatives and others 
working in public health and xenotransplantation research to discuss the following topics: 
 “What is a xenogeneic infectious disease event? What are some of the  problems 
associated with the development of standardized case definition?” 
 “What can be learned about characteristics of already existing and successful 
surveillance systems that might be applicable?” 
 “What are particular characteristics associated with xenotransplantation that must 
be accommodated in any developed surveillance systems for xenogeneic disease 
events?” 
 “What ethical considerations will need to be incorporated into a xenogeneic disease 
event surveillance system?” 
 “What might be a practical framework for international  surveillance?” 
 
Concluding, it can be said that the broad view of participants was, that an international 
surveillance system for xeno-associated infectious disease events is needed, regarding the 
number of clinical trials and the potential risk of xenogeneic pathogens (WHO, 2001b). 
The “WHO Guidance on Xenogeneic Infection/Disease Surveillance and Response: A Strategy 
for International Cooperation and Coordination” (WHO, 2001a) aims at facilitating the 
considerations for development and implementation of an international xenogeneic infection 
or disease event surveillance network for efficiently and effectively detecting, reporting and 
responding to such events using internationally harmonized, cooperative and coordinated 
surveillance activities (WHO, 2001a). 
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The resolution WHA57.18 of the 57th World Health Assembly (WHO, 2004) urges member 
states to carry out xenogeneic transplantation only when effective national regulatory control 
and surveillance mechanisms are in place, to cooperate in the formulation of 
recommendations and guidelines and to support international collaboration and coordination 
for the prevention and surveillance of xenogeneic infections. But it also requests the Director- 
General, amongst others, to provide technical support in strengthening capacity and expertise 
in the field of xenogeneic transplantation. 
This was followed by first Xenotransplantation Advisory Consultation in Geneva in 2005 (WHO, 
2005), succeeded by the “First WHO Global Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials”, whose recommendations were published as the 
“Changsha Communiqué” in 2008 (WHO, 2009). 
The “Second WHO Global Consultation on Regulatory Requirements for Xenotransplantation 
Clinical Trials” was held in Geneva, Switzerland in October 2011 (WHO, 2011) and deals, 
among other topics, with the current status of xenotransplantation science and practice and 
the discussion and refinement of draft guidance for infectious disease surveillance, prevention 
and response. 
In collaboration between WHO, International Xenotransplantation Association (IXA), and the 
Third Xiangya Hospital of the Central South University, Changsha, Hunan, China, the 10‐year 
anniversary of the “Changsha Communiqué” was celebrated with the organization of the 
“Third WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical 
Trials” in December 12‐14, 2018 (HAWTHORNE et al., 2019). The proposed revisions of the 
WHO documents resulted in the formulation of the draft “Third WHO Global Consultation on 
Regulatory Requirements for Xenotransplantation Clinical Trials, The 2018 Changsha 
Communiqué.”, which was submitted to WHO in February 2019 for WHO and World Health 
Assembly consideration. If it obtains approval, the 2018 Changsha Communiqué will be posted 
on the websites of WHO, IXA, and The Transplantation Society (TTS), and published in 
Xenotransplantation (HAWTHORNE et al., 2019). 
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2.3.2  Food and Drug Administration (FDA) 
 
The U.S. Food and Drug Administration (FDA) currently has three guidance documents 
regarding xenotransplantation published. 
The “Guidance For Industry: Public Health Issues Posed by the Use of Nonhuman Primate 
Xenografts in Humans” provides guidance to industry and researchers concerning the use of 
nonhuman primates as the source of cells, tissues and organs, the potential public health risks 
posed by nonhuman primate xenografts, the need for further scientific research and 
evaluation of these risks, particularly infectious agents and the need for public discussion 
concerning these issues (FDA, 1999). 
This guidance was followed by the U.S. Public Health Service (PHS) “PHS Guideline On 
Infectious Disease Issues in Xenotransplantation” in 2001 (FDA, 2001), which was developed 
to identify general principles of prevention and control of xenogeneic infectious diseases that 
may pose a risk to public health. It addresses the public health issues related to 
xenotransplantation and recommends procedures to minimize the risk of transmis sion of 
infectious agents to the recipients, medicinal personnel, close contacts and the general public. 
The recommendations given in the “Guidance for Industry: Source Animal, Product, 
Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in 
Humans” by the Food and Drug Administration (FDA), from 2003 and updated in 2016 claim, 
among others, that you should only derive animals from closed herds with documented health 
screening programs, that are accredited by the Association for Assessment and Accreditation 
of Laboratory Animal Care (AAALAC) (FDA, 2003). Furthermore, should the facilities not be 
built near any other agricultural or manufacturing facilities, as they are a source of infection. 
You should provide standard operation procedures (SOPs) for any activity that has in the 
broadest sense to be done with the animals or the animal facility. For example, to define the 
DPF status of the donor animals and the facility, initial screening and routine monitoring have 
to be done and therefore protocols and SOPs of these monitoring schemes should exist. In 
order to establish a list of pathogens to be screened for and which diagnostic test is 
appropriate, the FDA suggest to consult experts, such as infectious disease consultants, 
virologists, microbiologists, accredited microbiological laboratories, and veterinarians (FDA, 
2003). 
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Also, the storage and delivery of feed, water and any other consumables should be described, 
as well as it is advised to keep recordkeeping of the manufacturer, batch numbers in order to 
allow backtracking (FDA, 2003). 
SOPs for caretakers should include entry and exit procedures, clothing requirements and all 
other interactions that may take place between them and the animals. A documented training 
program for the caretakers and personnel according to current good manufacturing practices 
should regularly take place (FDA, 2003). 
Those are just few examples of the recommendations given in the “Guidance for Industry: 
Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of 
Xenotransplantation Products in Humans” by the FDA, which guides through the whole 
product manufacturing process, starting with the source animal and also advising on how to 
store the samples. 
 
2.3.3  European Medicines Agency (EMA) 
 
The “Committee For Medicinal Products For Human Use (CHMP)” from the European 
Medicines Agency (EMA) issued the “Guideline On Xenogeneic Cell-Based Medicinal Products” 
in 2009 (EMA, January 1, 2010). The guideline should be read together with the introduction 
and general principles (4) and part 4 of the Annex I to Directive 2001/83/EC, the Regulation 
(EC) No 1394/2007 on Advanced Therapy Medicinal Products and the Directive 2001/18/EC, 
when cells are obtained from genetically modified animals. First, the authors define 
xenogeneic cell-based therapy as the use of viable animal somatic cell preparations, which are 
suitably adapted for either implantation/infusion into a human recipient or extracorporeal 
treatment by bringing animal cells into contact with human body fluids, tissue or organs, 
where the principal objective is reconstitution of cell, tissue or organ functions (EMA, January 
1, 2010). This guideline is an annex to the guideline EMEA/CHMP/41086/2006 and deals 
specifically with scientific requirements unique for xenogeneic cell-based medicinal products . 
The main issues of the “Guideline On Xenogeneic Cell-Based Medicinal Products” are the 
source and the testing of the animals, manufacture and quality control and non-clinical and 
clinical development of xenogeneic cell-based medicinal products. Furthermore, it deals with 
public health aspects to ensure proper surveillance for infections, especially zoonoses. Sources 
for xenogeneic material can be non-transgenic, transgenic and genetically-modified animals. 
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Regarding quality and manufacturing aspects, there are three critical points given in the 
guideline: the source animals, the procurement and the processing of the organs, tissues and 
cells (EMA, January 1, 2010). The manufacturing facility should be good manufacturing 
practice (GMP) approved and separated from the animal facility. The health status of the 
animals should be monitored and documented, with special attention to organ and tissue 
specific pathogens. Further should the origin of the animals be fully described, e.g. typically 
for consumption or for laboratory use and they should be at least be specific pathogen free 
(SPF) and held under SPF conditions. The cells, tissues  and organs for manufacturing 
xenogeneic cell-based medicinal products should only be produced from animals bred in 
captivity, in a barrier facility, and only bred for this special purpose. Under no circumstances 
should cells, tissues and organs from wild animals or from abattoirs be used. Additionally, the 
tissue of founder animals should not be used. 
Cells, tissues or organs may be obtained from genetically modified animals, or may be 
obtained by ex vivo genetic modification. In any case, genetically modified animals must be 
fully characterized and have to comply with applicable European legislation. Animal cells from 
genetically modified animals used as active substance should comply with “Note for Guidance 
on the Quality, Preclinical and Clinical aspects of Gene Transfer Medicinal Products 
(CPMP/BWP/3088/99) (EMA, January 1, 2010). The guidance on risk assessment of gene 
therapy medicinal products in the guideline EMEA/CHMP/GTWP/125491/2006 can be useful 
for xenogeneic cell-based medicinal products as well. 
SOPs for the following procedures should be installed to avoid incidents that negatively affect 
the health of the herd or colony and thus could negatively impact on the barrier facility or the 
SPF status of the herd (EMA, January 1, 2010) : detailing the housing of the animals and the 
containment conditions. Water, bedding, source and handling of feed, including feeding. Entry 
and exit of the animals, animal transportation, identifying individual animals and recording 
their movements to, through and out of the facility. Disposition of animal tissues and dead 
animals and removal from production and disposal of the animals and their by-products. 
Performance and monitoring of health screening and isolation and quarantine. 
The “Guideline On Xenogeneic Cell-Based Medicinal Products” advises to use protocols for 
monitoring the herd and to introduce a herd health surveillance system with a complete 
documentation of all veterinary care that the animals received. The specific screening routines 
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should include physical examination and laboratory tests, where all infectious agents known 
to potentially infect the source species have to be considered. It recommends that there is no 
use of any antibiotics or vaccines in the source animals. But, if treatment of animals with any 
medicines is necessary for animal welfare reasons, the impact on the product should be 
evaluated and discussed with the competent authority. Any use of vaccines must be justified 
(EMA, January 1, 2010). 
As mentioned above the testing programs for source animals should be tailored for the 
purpose of the product and updated periodically to reflect advances in the knowledge of 
infectious disease. Adequate and validated diagnostic assays and methods have to be 
available before initiating clinical trials. Some pathogens to be considered are given in the 
“Guideline On Xenogeneic Cell-Based Medicinal Products”, e.g. endogenous retroviruses (ERV 
e.g. porcine ERV), infectious agents of humans relating to receptors expressed by transgenic 
animals (CD46 (membrane cofactor protein, MCP-1) as the cell-surface receptor for measles 
virus), antibiotic-resistant bacteria, geographically important infectious agents such as 
Trypanosoma cruzi or African Swine Fever. 
Adequate archiving is another crucial point to be discussed, because long-term archiving of 
tissue samples, cell preparations and paper records will be necessary (EMA, January 1, 2010). 
Records should be kept for 30 years, which makes an established and validated archiving plan 
inevitable, to ensure traceability and the possibility for look-back. All records concerning the 
herd, e.g. feeding and health records, source animal health documentation, should be 
archived for a period at least equal to that of the archived tissue samples. 
Giving a very good overview of the regulatory landscape, especially of cell therapy products in 
Europe, for example pancreatic islets and hepatocytes, the Review “Regulatory aspects of 
clinical xenotransplantation” from Henk-Jan Schuurman (reviewed in SCHUURMAN, 2015) has 
to be mentioned at this place. 
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2.3.4  Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) 
The Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
International is a private, nonprofit organization that promotes the humane treatment of 
animals in science through voluntary accreditation and assessment programs (AAALAC, 2019). 
It is proposed that facilities should achieve accreditation by AAALAC (reviewed in 
SCHUURMAN, 2015). By earning a voluntary AAALAC accreditation, the companies, 
universities, hospitals, government agencies and other research institutions show their 
commitment to responsible animal care and use (AAALAC, 2019). This is done through the 
accreditation process in which research programs demonstrate that they meet the minimum 
standards required by law, and are even going the extra step to achieve excellence in animal 
care and use. To acquire accreditation the “Guide for the Care and Use of Laboratory Animals” 
shall serve as a basic guide to the establishment of specific standards. 
In the “Guide for the Care and Use of Laboratory Animals” one of the key-concepts is, that all 
the people working, using, producing or caring for animals for testing, research or teaching 
must assume that they are responsible for the well-being of these animals (NRC, 2011). It 
establishes the minimum ethical, practice and care standards for researchers and their 
institutions. 
In chapter one, laboratory animals are defined as any vertebrate animal, e.g. traditional 
laboratory animals, agricultural animals, wildlife and aquatic species, produced for or used in 
research, testing or teaching (NRC, 2011). All personnel involved with the care and use of 
animals must be adequately educated, trained and/ or qualified in the basic principle of 
laboratory animal science to help ensure high-quality science and animal well-being. The 
opportunity and the support for regular professional development, training and continuing 
education should be given by the institutions (COLBY et al., 2007). 
Further, in chapter two with the heading “Animal Care and Use Program”, it is stated, that the 
selection of appropriate housing systems for the experimental animals should be carried out 
by specialists, as it needs professional knowledge and depends on the expected hazards and 
experiments that will be carried out. When experiments involving hazards are performed, 
special attention should be given to procedures for animal care and housing, storage and 
distribution of the agents, dose preparation and administration, body fluid and tissue 
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handling, waste and carcass disposal, items that might be used temporarily and removed from 
the site and of course personnel protection (NRC, 2011). 
Chapter three deals with environment, housing and management. Here the aspects like 
temperature, humidity, ventilation, air quality and illumination are described and the 
importance of environmental enrichment to enhance the animal well-being is stressed-out. It 
is further described how to estimate the space needs of animals correctly and what factors 
need to be considered regarding space estimation. The same issues are discussed for aquatic 
animals. 
Chapter four, “Veterinary Care”, is dedicated to the employment of an adequate veterinary 
care program, which consists of the assessment of animal well -being and the effective 
management of: animal procurement and transportation, preventive medicine, clinical 
disease, disability or related health issues, protocol-associated disease, surgery and 
perioperative care, anesthesia and analgesia and euthanasia (NRC, 2011). 
The last chapter deals with the physical plant itself and gives advice on how to plan, design, 
construct and properly maintain an animal experimental facility. It discusses the advantages 
and disadvantages of a centralized animal facility versus a decentralized facility and illustrates  
what has to be considered when special facilities, like a surgery, imaging or a whole body 
irradiation unit have to be built (NRC, 2011). 
As pigs are the preferred donor species in xenotransplantation, another very useful guide for 
animal housing, especially for agricultural animals is the “Guide for the Care and Use of 
Agricultural Animals in Research and Teaching” by the Federation of Animal Science Societies 
(FASS) (FASS, January 2010). In the USA, the “Guide for the Care and Use of Laboratory 
Animals” by the National Research Council (NRC) (NRC, 2011) and the “Guide for the Care and 
Use of Agricultural Animals in Research and Teaching” (FASS, January 2010) are the two 
guidelines which may be utilized when managing programs engaged in research, testing, and 
teaching with agricultural animals (SWANSON et al., 2018). Also, chapter 23 “Agricultural 
Animals” from the book “Management of Animal Care and Use Programs in Research, 
Education, and Testing” (2nd edition) by Janice C. Swanson, Larry T. Chapin, and F. Claire 
Hankenson provides an overview of the considerations regarding the care and use of 
agricultural animals, their environment and housing and it highlights the available resources 
to assist program managers, veterinarians, and research staff (SWANSON et al.,  2018). 
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2.3.5  Federation of European Laboratory Animal Science Associations (FELASA) 
 
The Federation of European Laboratory Animal Science Associations (FELASA) is an association 
from different European societies working in the field of laboratory animal science (BFR, 
2019). FELASA was founded in 1978 and the German “Gesellschaft für 
Versuchstierkunde/Society of Laboratory Animal Science” (GV-SOLAS) is also a member. 
FELASA organizes scientific congresses on a regular basis and publishes guidelines and 
recommendations regarding the whole field of laboratory animal science. GV-SOLAS is a 
registered society, which deploys itself for the responsible handling of laboratory animals (GV- 
SOLAS, 2013). 
In the report “FELASA recommendations for the health monitoring of breeding colonies and 
experimental units of cats, dogs and pigs” of the FELASA Working Group on Animal Health 
(REHBINDER et al., 1998) the authors give detailed information about the importance of an 
animal health monitoring program and the purpose of this recommendations, namely to 
harmonize the procedures, achieve similar standards  of testing and that reports have a 
common standard and format within the FELASA member countries (REHBINDER et al., 1998). 
Eleven general considerations have to be made according to the recommendations. For 
example, that the local variations through Europe affect the number of agents that have to be 
monitored, or, if diseases are declared absent by a national authority, they do not need to be 
monitored. Depending on local circumstances, e.g. colony size, regional prevalence of specific 
organisms or existence of national monitoring schemes, actual practice may exceed these 
recommendations. 
These recommendations are intended for all breeding colonies and experimental units of cats, 
dogs and pigs in biomedical research (REHBINDER et al., 1998). Further should each breeding 
unit be considered as a self-contained microbiological entity. SOPs must be available in the 
monitoring laboratories. Furthermore, should they follow GLP principles and participate in a 
Quality Assurance Program. 
If a pathogen is identified or antibodies to it are detected it must be declared as present, with 
the exception of vaccinated animals. The presence of antibodies against organisms for which 
it has not been vaccinated is an indicator of infection in the colony. It should be kept in mind, 
that negative results only state, that the presence of an agent monitored has not been 
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demonstrated in the animals screened by the tests used. Therefore, the results are not 
necessarily a reflection of the health status of all animals in the unit (REHBINDER et al., 1998). 
The written copies of vaccination and deworming policies should be provided and the brand, 
date and dose must be recorded when deworming or vaccination is done. Further should the 
information on the manufacturer, batch number and expiry date of the product be recorded. 
In non-barrier facilities most cats, dogs and pigs are vaccinated according to general conditions  
of the breeding colony, buyers’ requirements, on request and according to import/export 
regulations (REHBINDER et al., 1998). 
The health inspection of the colony should be assessed by a veterinarian at least every month 
and all animals must be observed daily by an animal technician (REHBINDER et al., 1998).  The 
samples for the routine health monitoring have to be taken from live animals, however they 
can be extended by samples obtained from dead or euthanized animals. Bacteriology, 
serology and parasitology are preferably monitored individually. 
At least every three months not less than ten randomly selected animals should be sampled, 
or sampling should take place according to the respective national disease control programs 
and import/export regulations. The main purpose of this health monitoring of experimental 
units is to provide the researchers with data on variables (pathogens, agents, diseases) that 
might influence their experiments (REHBINDER et al., 1998). These data are part of their work 
and have to be considered when interpreting the results. Therefore, results of health 
monitoring programs should be included in scientific publications. 
Where breeders or users of laboratory animals are reporting the results of a health monitoring 
program, which is in full accordance with the recommendations published by FELASA, the 
report should be titled “FELASA-Approved Health Monitoring Report” or they may also use the 
words “in accordance with FELASA recommendations” (REHBINDER et al., 1998). But this 
wording can only be used if the methods, frequency, sample size, species -list of organism 
monitored and reported are in full accordance with the recommendations published by 
FELASA (REHBINDER et al., 1998). 
In the report “FELASA recommendations for the health monitoring of breeding colonies and 
experimental units of cats, dogs and pigs” are lay-out advises for the “FELASA-Approved 
Health Monitoring Report” for each species, namely cat, dog and pig given (REHBINDER et al., 
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1998). Additionally, there are tables of the viral, bacterial and parasitic agents and suitable 
test methods for each pathogen shown. 
3 MATERIAL AND METHODS 50 
 
 
 
 
3 Material and Methods 
 
Major elements of my thesis have been included in different publications. For those parts, the 
relevant Material and Methods have been described in the respective manuscripts. The 
following section describes the Material and Methods used for tracing PERV-C proviruses in 
the genomes of the xenotransplantation breeding herds. 
 
3.1 PERV-C detection 
 
PCRs have been run on DNA isolated from porcine tissue by using Nexttec™ 1-Step Tissue & 
Cells DNA isolation kit (Nexttec™ Biotechnologie GmbH, Leverkusen, Germany) or the 
DNAeasy® Blood&Tissue kit (Qiagen, Hilden, Germany), according to the manufacturers´ 
protocols. For each PERV-C integration site, several primer pairs have been designed to detect 
either the abundance of solo-LTR, the entire provirus or the untouched genomic sites prior to 
integration. Eventually, one primer pair was optimized for reliable detection of each PCR. 
Sequences of the primers are listed in Table 2. Eventually, for each PCR a pair of primers have 
been chosen for routine detection under standard running conditions (Table 3 and Table 4). 
Each PCR was composed of the same constituents at the same volumes (Table 5). 
Primers used to establish PCRs to detect LTR and provirus sequences in the pigs, as well as to 
investigate the sites in the pigs’ genomes without PERV-C, where other pigs have PERV-C 
integrated are listed in Table 2. Primers used with the cycler protocol “PERVC1” are marked 
green and primers used with the cycler protocol “PERVC3” are marked blue.  
 
primer manufacturer sequence 
chr14:62_LTR_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-TGTGGAATGATAGATACTGGTTAAGAG 
chr14:62_LTR_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-AGACTAGGAGTCAGCAGAGTTTA 
chr14:62_LTR_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-GACAATTTGCACATAGCAGTGTA 
chr14:62_LTR_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-GGTGAGCTGAGGAAGGATTT 
chr14:62_prov_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-TGATCACTACAGTCTGCCAAAG 
chr14:62_prov_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-GTCCAATGGTCGAGAGTCAAA 
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chr14:62_prov_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-GTACATGCAGCCAACTGGTCA 
chr14:62_prov_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-AAGCAGGCAAAAGAGTCGGA 
chr4:48_LTR_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-AAGTGTCCTTGACTCCAGAAAG 
chr4:48_LTR_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-GGCCAGTGTCCCATCTTAAA 
chr4:48_LTR_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-GACTCCAGAAAGCCACAGTT 
chr4:48_LTR_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-GCCTTGACACAACAAGAGTTTC 
chr4:48_prov_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-TCAGGGAATGGTCAATGTATGG 
chr4:48_prov_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-ACTGCTTTAATAGCCAGGATAA 
chr4:48_prov_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-AGGATGCAGGCTTGAGACAG 
chr4:48_prov_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-CCTGAGAGGACAGCTGCAAA 
scf200_LTR_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-GCTGTCCGTTCTCATCTCAAA 
scf200_LTR_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-CAAGTAGCAGTTCCACCTTGTA 
scf200_LTR_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-TCCTGAAGACGGTGTCCTCT 
scf200_LTR_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-TTAAAACTGCCGAGGGAGCC 
scf200_prov_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-CATGGCCTCCTAAGCTTTCT 
scf200_prov_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-TGCCAAGGTCCCTTCTTAAC 
scf200_prov_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-GTGCATACGCGGTTTCCTTC 
scf200_prov_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-GGACAGCTGCAAACCGAAAG 
chr11:29_LTR_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-TCTTGAACTACACACAGACATCA 
chr11:29_LTR_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-TCTTGTGACAGAGTATTTCCAGCA 
chr11:29_LTR_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-TATTTAAACCATATGCCAGATAAGCAC 
chr11:29_LTR_r_2 biomers.net GmbH, 
Ulm, Germany 
5'- 
TGCTAAGTATACATAACATTTGACATTCT 
chr11:29_prov_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-TCTTGAACTACACACAGACATCATA 
3 MATERIAL AND METHODS 52 
 
 
 
 
chr11:29_prov_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-TGCCAAGGTCCCTTCTTAAC 
chr11:29_prov_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-TTCTTGAACTACACACAGACATCA 
chr11:29_prov_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-GTTTAACCCATGGCGGAGGA 
scf141_LTR_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-CTGCATTCTGCAAAGGGAAAC 
scf141_LTR_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-CTGAGCCAAGCCGCATTA 
scf_141_LTR_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-CACTGCTGCTTGGCTGGTGGTA 
scf_141_LTR_r2 biomers.net GmbH, 
Ulm, Germany 
5'-ACACAAAGCGCGCTTCTAGGA 
scf_141_prov_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-CCTATCAGGAGAAAGAGACTT 
scf_141_prov_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-TAATGCGGCTTGGCTCAG 
scf_141_prov_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-CCAAAGCCCGTCTAGCAGGAAA 
scf_141_prov_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-ACACAAAGCGCGCTTCTAGGA 
chr7:23_LTR_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-GTATTGTTCTGGAGGGCTTGTG 
chr7:23_LTR_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-GTAAACCATATATTATTC 
chr7:23_LTR_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-ATCTTCACCACGGCTGTAGCT 
chr7:23_LTR_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-ATGGAACTTCCCAGGC 
chr7:23_prov_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-CACGGCTGTAGCTCAATCTTAT 
chr7:23_prov_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-GGTCCCTTCTTAACCTGAACTG 
chr7:23_prov_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-TCTGCCTGGTGGGTTGAAAG 
chr7:23_prov_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-GGACAGCTGCAAACCGAAAG 
chrX:32_LTR_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-GTGTGAGAGTGTGTTCTAGT 
chrX:23_LTR_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-GAATCCTTCCCTGGAATAC 
chrX:32_LTR_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-AATATTCATGAGGTTGATG 
chrX:32_LTR_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-TTCACAAAACTAGAACAATCG 
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chrX:32_prov_f_1 biomers.net GmbH, 
Ulm, Germany 
5'-GATGGTGTCCTGTCGTA 
chrX:32_prov_r_1 biomers.net GmbH, 
Ulm, Germany 
5'-TCGGTCCTCTGACCG 
chrX:32_prov_f_2 biomers.net GmbH, 
Ulm, Germany 
5'-TAAGCCCTTGTCAGTTGCA 
chrX:32_prov_r_2 biomers.net GmbH, 
Ulm, Germany 
5'-AGATCCAGACACACGTGACC 
PervCexc1.3_1f biomers.net GmbH, 
Ulm, Germany 
5'-CGGAAGTGACGACACAGGAA 
PervCexc1.3_1r biomers.net GmbH, 
Ulm, Germany 
5'-TGAATGTGCACGACGGGTTA 
PervCexc1.3_2f biomers.net GmbH, 
Ulm, Germany 
5'-CTGACAGGTAATGGGTCATCAG 
PervCexc1.3_2r biomers.net GmbH, 
Ulm, Germany 
5'-GACGGGTTCAAGAGGTGAAA 
PervCexc1.3_3f biomers.net GmbH, 
Ulm, Germany 
5'-TTTCCGCATCCGATAGCCTC 
PervCexc1.3_3r biomers.net GmbH, 
Ulm, Germany 
5'-GGGACCCCTGTTTCTACAGC 
PervCexc1.3_4f biomers.net GmbH, 
Ulm, Germany 
5'-AGCCACGCTAATCCGAAACA 
PervCexc1.3_4r biomers.net GmbH, 
Ulm, Germany 
5'-TTTCCTTTCTCCCGCTTCCC 
PervCexc1.20_1f biomers.net GmbH, 
Ulm, Germany 
5'-TTGCCTGCCTTGCTAATCTC 
PervCexc1.20_1r biomers.net GmbH, 
Ulm, Germany 
5'-GCTTCTGGTTGTCCCTTCTATG 
PervCexc1.20_2f biomers.net GmbH, 
Ulm, Germany 
5'-TCGGTTCTCCCTCTTTCTCT 
PervCexc1.20_2r biomers.net GmbH, 
Ulm, Germany 
5'-TTTAAGCAGGGCTGGTAAGG 
PervCexc1.20_3f biomers.net GmbH, 
Ulm, Germany 
5'-CCTTCGCTCTCCCAGGATTC 
PervCexc1.20_3r biomers.net GmbH, 
Ulm, Germany 
5'-ATAAAGCACCCTGGAGGCAC 
PervCexc1.20_4f biomers.net GmbH, 
Ulm, Germany 
5'-CAACTGTCCTGTCCATCCCC 
PervCexc1.20_4r biomers.net GmbH, 
Ulm, Germany 
5'-CCCCTTTTCCTGACATCCCC 
PervCexc5.23_1f biomers.net GmbH, 
Ulm, Germany 
5'-AGCTTTACCCTCCCATCCCT 
PervCexc5.23_1r biomers.net GmbH, 
Ulm, Germany 
5'-TCAGGGATCGAACCTGCAAC 
PervCexc5.23_2f biomers.net GmbH, 
Ulm, Germany 
5'-GTTCAGACCATCAGGGCTCC 
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PervCexc5.23_2r biomers.net GmbH, 
Ulm, Germany 
5'-GTCAGGGATCGAACCTGCAA 
PervCexc5.23_3f biomers.net GmbH, 
Ulm, Germany 
5'-CTTCTGAATCTGGCAGGTAAGG 
PervCexc5.23_3r biomers.net GmbH, 
Ulm, Germany 
5'-GTCTTCAGCCCAAGAAGTATGT 
PervCexc5.23_4f biomers.net GmbH, 
Ulm, Germany 
5'-CTGACTCTGCTCCACCAATAG 
PervCexc5.23_4r biomers.net GmbH, 
Ulm, Germany 
5'-ACCAGGCTCTTAAACCATCTC 
PervCexc5.23seq1f biomers.net GmbH, 
Ulm, Germany 
5'-TGATACTCTTTTACAATTTTGGG 
PervCexc5.23seq1r biomers.net GmbH, 
Ulm, Germany 
5'-AGACAACAGGAATGCTGAAGAAGGG 
PervCexc1.20seq1f biomers.net GmbH, 
Ulm, Germany 
5'-CCAATGTATCCATGTAAATTTCCC 
PervCexc1.20seq1r biomers.net GmbH, 
Ulm, Germany 
5'-GGGTGTGTGCAAAGGGGAGTGAG 
PervCexc1.3seq1f biomers.net GmbH, 
Ulm, Germany 
5'-GCGTTTGGGAAGAGGGAGGG 
PervCexc1.3seq1r biomers.net GmbH, 
Ulm, Germany 
5'-GCCAGCTTCAGCCTGGGC 
 
 
Table 2 Primers used for establishing PCRs to detect PERV-C sites in the pig genome. Primers  
of optimized PCRs are marked in green when used with the cycler protocol “PERVC1” or 
marked in blue when eventually used with the cycler protocol “PERVC3”. Primers located 
within the respective amplicons used for Sanger sequencing carry the abbreviation “seq”.  
 
 
 
 
 
Established PCR protocols and mastermix for the later used primer pairs: 
 
 
 
 
 
Table 3 Cycler protocol “PERVC1” used for 
various primer pairs. 
Table 4 Cycler protocol “PERVC3” used for 
two primer pairs. 
  95°C  5min  
94°C 30 sec 
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number of samples 1 5 
H2O 14 70 
dNTPs 2 10 
10x CoralLoad PCR buffer 2 10 
MgCl 0 0 
For primer 0,4 2 
Rev primer 0,4 2 
HST Taq 0,2 1 
 
 
Table 5 Mastermix for PCRs with HotStarTaq Plus DNA Polymerase. 
 
 
 
 
Sanger sequencing was done according to the established protocol in our laboratory. PCR 
products were extracted from blocks of agarose that have been excised from electrophorese 
gels by a scalpel under UV-light control by using either the “Double Pure Kombi Kit” (Bio&Sell 
GmbH, Feucht/Nürnberg, Germany) or “NucleoSpin® Gel and PCR Clean-up” (Macherey- 
Nagel, Düren, Germany). The chain termination reaction was performed by using BigDye™ 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems™, Waltham, Massachusetts, USA) 
(Table 6 and Table 7). Cleanup of the sequencing reaction was performed by high-salt/Ethanol 
precipitation (Table 8). Capillary electrophoresis of the purified sequencing reactions was 
performed at the Helmholtz Center Munich (Neuherberg, Germany). 
 
 
 
 
number of samples+2  
 x 4µl 5xSequencing Buffer 
 x 1µl BigDye 
 x 1µl Primer (10µM Stock) 
 x 2µl H2O 
 + 2µl Template 
 
 
Table 6 Composition of Sanger sequencing reaction. 
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  95°C  1 min  
95°C 10 sec 
} 40 x 
n               
54°C 10 sec 
  60°C  4 mi 
4°C 15 min  
 
 
Table 7 Cycler protocol of the Sanger sequencing reaction. 
 
 
 
 
Always fresh preparing of precipitation mix: 
number of samples + 5 x 10µl H2O 
x 5µl 125mM Ethylendiamintetraazetat (EDTA) 
x 60µl 100% Ethanol (EtOH) = total amount 
Mix each sequencing sample with 75µl of precipitation mix and transfer to a new, labelled 
1.5ml Eppendorf tube 
Let it incubate on ice for 15 minutes 
Centrifugate at 13000 rounds per minute (rpm) at 4°C for 30 minutes  
Pay attention to the direction in which the Eppendorf tubes were placed into the centrifuge, 
because of the pellet, which will be there on the ground of the tube 
Take off the supernatant carefully with two pipet tips, without filter, placed on top of each 
other 
Afterwards, wash the pellet with 70% EtOH, which means shortly vortexing the pellet with 
the EtOH on top of it 
Then, centrifugate again at 13000 rpm for 2,5 minutes  
Take off the supernatant EtOH with the two-pipet tip technique 
Let the pellet air dry for exactly 6 minutes 
Resolve again in 30µl H2O, vortex shortly, spin down in the centrifuge for a few seconds  
afterwards and transfer to 96-well sequencing plate 
 
 
Table 8 Clean-up protocol of the Sanger sequencing reaction. 
3 MATERIAL AND METHODS 57 
 
 
Sequencing data were analyzed as electropherograms by using FinchTV v.1.3.1/ FinchTV 
v.1.4.0 software and aligned compared to the corresponding sequences from the SusScrofa 
reference genome 11.1 (www.ensembl.org) in BioEdit. 
 
 
 
 
 
Materials used in the laboratory and stable to acquire and process the samples: 
 
product manufacturer 
Thermocycler GeneAmp® PCR System 9700 Applied Biosystems™, Waltham, 
Massachusetts, USA 
Gel Doc 2000 BioRad, Hercules, California, USA 
power supply unit Powerpack 300 BioRad, Hercules, California, USA 
Thermoshaker TS100 / Block SC-24n bioSan, Riga, Lettland 
PCR Strips of 8 caps Brand, Wertheim, Germany 
PCR Strips of 8 tubes Brand, Wertheim, Germany 
Microwave Severin 900 Severin, Sundern, Germany 
Eppendorf Centrifuge 5424 Eppendorf, Hamburg, Germany 
Eppendorf Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Pipet tips epT.I.P.S.® Standard, Eppendorf 
Quality™, 2 – 200 µL, 53 mm, yellow 
Eppendorf, Hamburg, Germany 
Pipet tips epT.I.P.S.® Standard, Eppendorf 
Quality™, 50 – 1000 µL, 71 mm, blue 
Eppendorf, Hamburg, Germany 
Pipet tips epT.I.P.S.® Standard, Eppendorf 
Quality™, 0.1 – 10 µL S, 34 mm, dark grey 
Eppendorf, Hamburg, Germany 
Pipets Gilson (P2, P10, P20, P100, P200, 
P1000) 
Gilson Inc., Middleton, WI 53562- 
0027, USA 
Water bad JBN 5 Grant Instruments LTD, Shepreth, 
Royston SG8 6GB, UK 
Pipet tips A20S Kisker, Steinfurt, Germany 
Pipet tips A200S Kisker, Steinfurt, Germany 
Pipet tips A1000S Kisker, Steinfurt, Germany 
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Pipet tips A300SX Kisker, Steinfurt, Germany 
Pipet tips A100S Kisker, Steinfurt, Germany 
Rotina 380 R Hettich Zentrifugen, Tuttlingen, 
Germany 
Microcentrifuge CarlRoth, Karlsruhe, Germany 
Labcycler Basic SensoQuest, Göttingen, Germany 
Labcycler Gradient SensoQuest, Göttingen, Germany 
Sony UP-895CE (photo printer) Sony, Minato, Tokio, Japan 
OWL EASYCAST™ B2 (gel chamber with tray 
and combs) 
ThermoScientific, Waltham, 
Massachusetts, USA 
OWL EASYCAST™ A1B (gel chamber with tray 
and combs) 
ThermoScientific, Waltham, 
Massachusetts, USA 
VWR Labdancer VWR International GmbH, 
Darmstadt, Germany 
MK-2000B (scale) Chyo, Japan 
Spectrometer SimpliNano with printer GE Healthcare Life Sciences, UK 
Safe-Lock Tubes (1,5 ml, 2 ml, 5 ml) Eppendorf, Hamburg, Germany 
Measuring cylinder Labsolute® Th. Geyer, Renningen, Germany 
Erlenmeyer flask Simax® Kavalierglass, 285 06 Sázava, Czech 
Republic 
glasbottles Duran® (1l, 500ml, 250ml) DWK Life Sciences, Wertheim, 
Germany 
Autoklav Varioklav 400 HP Medizintechnik, 
Oberschleißheim, Germany 
gloves SafeGrip Süd-Laborbedarf, Gauting, 
Germany 
Ethanol ROTIPURAN ® ≥99,8%, p.a.; Art.-Nr. 
9065.4 (EtOH) 
CarlRoth, Karlsruhe, Germany 
Agarose universal; Art.-Nr. BS20.46.500 BIO&SELL, Feucht/Nürnberg, 
Germany 
Tris Pufferan ≥99,9%, p.a.; 2M; Art.-Nr. 4855.2 CarlRoth, Karlsruhe, Germany 
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EDTA ≥99% 50mM, p.a., ACS; Art.-Nr. 8043.2 CarlRoth, Karlsruhe, Germany 
100 mM dNTP Set, PCR Grade Invitrogen, Karlsruhe, Germany 
GeneRuler 1 kb DNA Ladder ThermoScientific, Waltham, 
Massachusetts, USA 
GELRED 10000x in water Biotium, Fremont, CA 94538, USA 
Bromophenol blue sodium salt for 
electrophoresis; Art.-Nr. A512.1 
CarlRoth, Karlsruhe, Germany 
Dry ice AirLiquid, France 
Trichloromethane/chloroform 
ROTIPURAN® ≥99 %, p.a. (CHCl3) 
CarlRoth, Karlsruhe, Germany 
caustic soda 5 mol/l (NaOH) CarlRoth, Karlsruhe, Germany 
DNeasy® Blood&Tissue Kit Qiagen, Hilden, Germany 
Nexttec™ 1-Step Tissue & Cells 
DNA isolation Kit 
Nexttec™ Biotechnologie GmbH, 
Leverkusen, Germany 
NucleoSpin® Gel and PCR Clean-up (250 preps) Macherey-Nagel, Düren, Germany 
HotStarTaq Plus DNA Polymerase Qiagen, Hilden, Germany 
Herculase II Fusion DNA Polymerase Agilent, USA 
BigDye™ Terminator v3.1 Cycle Sequencing Kit Applied Biosystems™, Waltham, 
Massachusetts, USA 
Double Pure Kombi Kit Bio&Sell GmbH, Feucht/Nürnberg, 
Germany 
Tailcropping-transfomer 230 V 
(„Schwanzkupiertrafo “) 
BEG Schulze Bremer GmbH, 
Dülmen-Rorup, Germany 
 
 
Programmes used: 
 
name of the programme provider 
BioEdit Sequence Alignment Editor 7.0.5.2/7.0.5.3 BioEdit 
FinchTV v.1.3.1/ FinchTV v.1.4.0 Geospiza Inc. 
Quantity One Bio-Rad 
Jalview (WATERHOUSE et al., 2009) www.jalview.org 
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4 Results 
 
During the preparation of my doctoral thesis, I worked on the multi-genetically modified 
breeding herd of donor pigs for xenotransplantation. The main focus of my work was laid in 
the examination of the hygiene status of the existing xenotransplantation donor herds at the 
Lehr- und Versuchsgut Oberschleißheim (LVG) and the sanitation of the hygiene status during 
the population of CiMM. This included exogenous as well as endogenous pathogens. This work 
was accompanied by the management of the existing donor herds at the LVG and the 
production of multi-modified piglets for pre-clinical research (Figure 1). Imbedded in the CRC 
TRR 127 there are two projects that I supplied with pigs. The C8 project managed by Prof. 
Reichart performing the pig-to-baboon xenotransplantation trials (LANGIN et al., 2018) (Table 
9) and the C3 project, conducted by Prof. Seissler transplanting neonatal pig islet-like cell 
clusters, expressing LEA29Y into diabetic mice (KLYMIUK et al., 2012a; BUERCK et al., 2017) 
(Table 10). During my thesis I contributed to 4 accepted publications, on one of them I am the 
sole first author (see 4.1 – 4.4). In addition, I worked on the examination of PERV-C proviral 
integration sites (see 4.5). 
 
 
 
 
Figure 1 Establishing multi-modified donor pigs for xenotransplantation by combinatorial 
breeding. (provided by N.Klymiuk) 
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boar sow date piglets desired genotyp used in C8 
4667 4775 28.02.2017 11 8x GTKO.hCD46.hTBM 4x --> C8 
5001 4776 20.07.2017 7 2xGTKO.hCD46.hTBM 2x --> C8 
5001 5022 02.08.2017 6 3xGTKO.hCD46.hTBM / 
5001 5297 04.09.2017 8  / 
5001 4775 26.09.2017 6 1xGTKO.hCD46.hTBM 1x --> C8 
5003 5160 28.09.2017 6 4xGTKO.hCD46.hTBM 2x --> C8 
5154 4672 24.10.2017 10 4xGTKO.hCD46.hTBM / 
5155 5295 14.12.2017 3 1xGTKO.hCD46.hTBM / 
5154 4776 18.12.2017 5 5xGTKO.hCD46.hTBM 5x --> C8 
5001 5022 22.12.2017 4  / 
5154 5019 16.01.2018 13 8xGTKO.hCD46.hTBM / 
5154 5426 26.01.2018 2 2xGTKO.hCD46.hTBM / 
5001 5160 01.03.2018 8 1xGTKO.hCD46.hTBM / 
5001 4775 15.03.2018 9 4xGTKO.hCD46.hTBM / 
WT 4776 02.08.2018 7  / 
5411 5426 20.07.2018 3 2xGTKO.hCD46.hTBM / 
5001 4775 02.08.2018 8 3xGTKO.hCD46.hTBM / 
5411 5637 10.08.2018 3 3xGTKO.hCD46.hTBM 3x --> C8 
5001 5295 10.10.2018 7 2xGTKO.hCD46.hTBM 2x --> C8 
5625 5700 31.10.2018 7 2xGTKO.hCD46.hTBM / 
5001 5160 02.11.2018 6  / 
5625 5806 28.11.2018 9 5xGTKO.hCD46.hTBM 3x --> C8 
5001 4776 17.12.2018 3 1xGTKO.hCD46.hTBM / 
5001 5637 09.03.2019 14 2xGTKO.hCD46.hTBM 2x --> C8 
5625 5700 28.03.2019 9 2xGTKO.hCD46.hTBM 2x --> C8 
5411 WT 13.06.2019 13  / 
5001 6087 07.07.2019 4 1xGTKO.hCD46.hTBM / 
5411 5019 11.08.2019 4 2xGTKO.hCD46.hTBM 2x --> C8 
5625 5700 21.08.2019 9 5xGTKO.hCD46.hTBM 3x --> C8 
 
Table 9 All matings and offspring generated for the C8 project of the CRC TRR 127. 
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boar sow date piglets desired genotypes used in C3 
4682 5019 09.07.2017 9 8xGTKO   / 
5003 5160 28.09.2017 6    / 
5003 5297 16.03.2018 9 1xGTKO 3xGTKO.bLEA 2xGTKO.hCD46.bLEA 3x --> C3 
5003 5019 13.06.2018 9 2xGTKO 1xGTKO.bLEA 3xGTKO.hCD46.bLEA 4x --> C3 
5003 5297 17.08.2018 8 1xGTKO 3xGTKO.bLEA 4xGTKO.hCD46.bLEA 3x --> C3 
5625 WT 10.01.2019 12    / 
5003 5019 08.02.2019 12 1xGTKO 1xGTKO.bLEA 3xGTKO.hCD46.bLEA / 
5626 5297 08.02.2019 9   4xGTKO.hCD46.bLEA / 
5626 WT 14.06.2019 10     
5626 5297 01.07.2019 2     
 
Table 10 All matings and offspring generated for the project C3 of the CRC TRR 127. 
 
 
 
4.1 Population and raising up the xenotransplantation herd at CiMM 
 
In the manuscript “Early weaning completely eliminates porcine cytomegalovirus from a 
newly established pig donor facility for xenotransplantation” we document the ability to 
sanitate the hygiene status of an existing herd comprising multiple genetic modification by 
populating a new facility with pregnant sows from a barrier facility, the motherless raising of 
their offspring and the usage of the female offspring as recipients of genetically modified 
embryos. I contributed personally by aiding the veterinary herd management of both the 
embryo transfer recipient as well as the genetically modified offspring; by taking blood, stool 
and nasal samples and the orchestration of their analysis; by co-writing of the manuscript. 
(The supplementary table S1 can be found in the appendix) 
 
The approved manuscript can be found at Xenotransplantation. 2018 Jul;25(4):e12449. doi: 
10.1111/xen.12449. 
https://doi.org/10.1111/xen.12449 
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ABSTRACT 
For clinical xenotransplantation, transplants must be free of porcine cytomegalovirus 
(PCMV). Piglets become infected primarily in the perinatal period by the mother sow. While 
individual donor animals can be protected from infection by isolation husbandry, success is 
not guaranteed and this strategy poses the risk of undetected infections and raises animal 
welfare questions. Here, we present the establishment of a completely PCMV- negative pig 
herd for breeding donor animals for xenotransplantation. Eleven pregnant DanAvl Basic  
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hybrid sows were purchased from a designated pathogen- free (DPF), PCMV- positive colony 
and transferred to a new pig facility at the Centre for Innovative Medical Models (CiMM) 4 
weeks prior to farrowing. At the age of 24 hours, piglets were early- weaned and transferred 
to a commercially available Rescue Deck system dedicated to motherless rearing of piglets. 
Sows were removed from the facility. The PCMV status of F1- generation animals was 
determined at regular intervals over a period of 14 months by a sensitive real- time PCR- 
based detection method testing blood, nasal swabs and cultured peripheral blood 
mononuclear cells (PBMCs). F1 sows were used as recipients of genetically modified 
embryos to generate a xenotransplant donor herd. Offspring were tested for PCMV 
accordingly. All offspring have remained PCMV negative over the whole observation period 
of 14 months. A completely PCMV- negative pig herd for xenotransplantation has thus been 
successfully established. 
 
KEYWORDS 
early weaning, pig-to-human xenotransplantation, porcine cytomegalovirus, virus safety 
 
 
 
 
 
 
1. INTRODUCTION 
With recent successes in overcoming the major immunological hurdles in 
xenotransplantation1-4, the goal of reaching clinically feasible pig-to-human transplantation 
has become imminent. With this, the second great obstacle, the microbiological safety of 
potential donor tissues and organs, demands attention. After organ allotransplantation, 
opportunistic exogenous viral infections are rare, but happen, as the antiviral immune 
response is diminished by immunosuppression. Over almost 20 years, this issue has been 
discussed in the field of xenotransplantation and, over time, a number of consensus papers 
and pathogen lists have been published regarding potentially harmful microorganisms in the 
context of xenotransplantation5-7. Additionally, transmission of pathogens with viable cells 
poses a very efficient direct infection route via the transplant8. In a very recent publication, 
Fishman9 draws an updated list of pathogens that may be considered in the development of 
a screening program for xenotransplant donor pigs. 
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While most of these pathogens are sufficiently controlled by housing animals within 
barrier facilities and thus protecting them from exogenous infections, porcine endogenous 
retroviruses (PERVs) are a more precarious issue as they can be transmitted via the germline. 
Consequently, PERVs have caused considerable concern for clinical xenotransplantation. But 
to date there has been no report of PERVs being actually transmitted to the recipient of a 
xenograft or having caused detectable adverse reactions within a transplant10. Recent 
successes in eliminating PERVs from the genome of pig lines have further diminished this 
potential hazard11,12. Other pathogens, however, provoke lifelong, latent, transmittable 
infections, and are prevalent in most, if not all, pig populations and are thus difficult to control. 
These include the porcine cytomegalovirus (PCMV), a β-herpesvirus related to the human 
cytomegaloviruses that causes systemic disease and potentially leads to graft failure in human 
allotransplantation13. In xenotransplantation, the PCMV has also been associated with 
transplant injury. This has been largely attributed to virus activation within the graft following 
transplantation but initially was not thought to cause invasive disease in the recipient14,15. It 
is still unclear whether PCMV can infect human cells, with one in vitro study suggesting the 
possibility16 and a different study presenting evidence for the opposite17. There are indications 
that while in vitro PCMV appears susceptible to standard antiviral medication comparable to 
that employed in allotransplantation18, in vivo data from pig-to-baboon xenotransplantation 
suggest that the commonly used ganciclovir has no therapeutic efficacy against PCMV at 
standard doses19. Agents that do prevent or treat PCMV infection effectively, such as foscarnet 
or cidofovir, carry significant toxic potential for the transplant recipient and are thus of limited 
usefulness. Consequently, there is consensus that potential donor animals for 
xenotransplantation should be free of PCMV. 
Pigs are mostly infected with PCMV in the perinatal period by the mother sow or 
postnatally through oronasal secretions of virus shedding animals 20. The virus is endemic in 
pig herds worldwide20,21. To avoid transmission of virus from infected mother sows to 
offspring, contact between sows and piglets has to be minimized. With strategies of early 
weaning within the first 2 weeks after birth and separate rearing of early-weaned piglets, it 
has previously been possible to generate individual PCMV-negative pigs as organ donors20-2 4 . 
However, success was not reliably predictable and came at the immense effort of having to 
raise all potential donor animals motherless in isolation. 
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In this study, we report on the design and implementation of a strategy of very early 
weaning to generate a completely PCMV-free donor breeding herd for xenotransplantation in 
a newly established pig facility for biomedical research at the Centre for Innovative Medical 
Models (CiMM), LMU Munich, Germany. We show that with weaning at an age of 24 hours 
and subsequent immediate removal of all PCMV-positive mother sows from the facility, we 
have been able to generate a herd of PCMV-negative sows. In a subsequent step, we utilized 
these sows as recipients for embryo transfer to introduce all our genetically modified (gm) pig 
lines for xenotransplantation into the facility. All recipient sows and all gm offspring have 
stayed PCMV negative over the total observation period of 14 months. To our knowledge, this 
is the first report of a completely PCMV-negative pig facility that allows for conventional 
breeding of donor animals for xenotransplantation without further need for separate rearing 
of individual animals in isolation. 
 
2. MATERIAL AND METHODS 
 
 
2.1 Ethics Statement 
All animal work was performed with the permission of the local regulatory authority, 
Regierung von Oberbayern (ROB), Sachgebiet 54, 80534 München (approval number: 55.2-1- 
54-2532.0-82-2016). Applications were reviewed by the ethics committee according to §15 
TSchG (German Animal Welfare Act). 
2.2 Populating CiMM 
For establishing the breeding herd for xenontransplantation, eleven pregnant PCMV-positive 
DanAvl basic hybrid sows were purchased from a designated pathogen-free (DPF) barrier 
facility (Vermarktungsgemeinschaft für Zucht- und Nutzvieh e.G., Fehmarn Hof 
Schweinehaltungs KG, Fehmarn, Germany) located on the island of Fehmarn in the Baltic Sea 
and introduced into CiMM 4 weeks prior to their farrowing date (Figure 1). These sows were 
the founder population for CiMM (F0 generation). They were screened for PCMV 28 days 
before and 1 day after farrowing (Table 1). On gestation day 114, birth was induced by 
intramuscular administration of 0.175 mg cloprostenol (Estrumate®, Intervet GmbH, 
Unterschleissheim, Germany). After birth, offspring (F1 generation) were separated from the 
mother sow immediately and held in groups in isolation boxes under infrared light. Once every 
2 hours, piglets were allowed to suckle colostrum under supervision to prevent oronasal 
4 RESULTS 67 
 
 
contact between sows and their litters. After 24 hours, all F0 sows were removed from CiMM 
and the 91 F1 piglets were weaned to a motherless rearing system (Rescue Deck, Provimi 
Rescue Decks). Here, they were raised with designated milk replacers (Bonimal SB Powermilk, 
BayWa, Germany) and mash feed (Bonimal SB Liquidstart 2.0, BayWa, Germany) over a period 
of 3 weeks after which they were transferred to the regular holding pens within the facility 
(Figure 1). All F1-generation animals were screened for PCMV at different time points over a 
total time period of 14 months (Table S1). Upon reaching sexual maturity, PCMV-negative F1 
sows were utilized as recipients for embryo transfer to introduce gm-modified pig lines into 
CiMM. Embryos were produced by either somatic cell nuclear transfer (SCNT) 25 or in vitro 
fertilization (IVF) 26. For SCNT, pig primary kidney cells were isolated from existing gm pig 
lines27 and used as nuclear donor cells. For IVF, epididymidal sperm was collected from gm 
boars to fertilize oocytes isolated from slaughterhouse ovaries. SCNT and IVF embryos were 
treated with 0.25% trypsin according to the International Embryo Technology Society (IETS) 
embryo-treatment protocol28 and transferred to the estrus-synchronized recipient sows 
(Figure 2). 
Gm-modified offspring farrowed from the PCMV-negative F1 sows were then tested 
for PCMV at one single time point (Table 2). 
 
 
 
 
2. 3 In vivo sampling of pigs 
Blood sampling from adult sows was performed without sedation under manual 
fixation. Whole blood was drawn from the jugular vein with single-use needles (Ehrhardt 
Medizinprodukte, Geislingen, Germany) into lithium heparin and serum Monovettes® 
(Sarstedt, Nümbrecht, Germany). Nasal swabs were taken during the same procedure by 
inserting sterile dry swabs into one nostril, without touching outer skin, to collect nasal 
mucosa and capillary blood (Henry Schein, Hamburg, Germany). Lithium heparin blood and 
swabs were then cooled to 4°C and used freshly for analysis. Serum was centrifuged at 6°C, 
1800 g for 10 minutes, then aliquoted to 1mL samples and stored at -80°C. For piglets, all 
blood sampling was performed accordingly. Oral swabs were taken during the firs t sampling 
procedure at an age of 1 day. For this, similar swabs as employed for nasal probing were 
inserted into the mouth of the piglets to collect mucous membrane from the palate. 
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2. 4 Ex vivo sampling of pigs 
ET-recipient F1 sows were euthanized under ketamine (Ursotamin®, Serumwerk Bernburg, 
Germany) and azaperone (Stresnil®, Elanco Animal Health, Bad Homburg, Germany) 
anesthesia by intravenous injection of T61® (Intervet GmbH), according to the manufacturer’s 
instructions. Whole blood was drawn directly from the heart, and the following organs were 
sampled: liver, lung, heart, pancreas, spleen, kidney, and lymph nodes. Small pieces of about 
5x5x5 mm in size were excised from each organ and frozen to the core by placing them on dry 
ice plates. They were then transferred to pre-cooled Eppendorf tubes (Eppendorf, Hamburg, 
Germany) and stored at -80°C. Whole blood was aliquoted in 1mL Eppendorf tubes and also 
stored at -80°C. Organ samples from stillborn, dead, or euthanized offspring were collected as 
described above. For these animals, sampling of liver, spleen, whole blood, serum, and, if 
possible, bile was performed. All samples were stored at -80°C until analysis. 
 
2. 5 Screening Strategy 
Blood and nasal swabs of F0 sows were tested for PCMV 28 days before and 1 day after 
farrowing (Table 1). All 91 F1 piglets were screened repeatedly over a period of 14 months for 
the presence of PCMV (Table S1). Nineteen piglets born from these animals were tested at 
one time point when piglets were between 14 and 30 days old (Table 2). Additionally, organs 
of stillborn, dead, or euthanized piglets were sampled and examined for PCMV infection. 
Regular hygiene monitoring is performed, and representative numbers of the present 
pig population within the facility are examined for the presence of a range of pathogens on 
serological and antigenic level. Serological testing for Actinobacillus pleuropneumoniae, 
Haemophilus parasuis, Lawsonia intracellularis, Leptospira spp., Mycoplasma 
hyopneumoniae, Pasteurella multocida, porcine reproductive and respiratory syndrome virus, 
swine influenza virus, transmissible gastroenteritis, and hepatitis E virus, as well as antigen 
testing for Brachyspira hyodysenteriae, Lawsonia intracellularis, salmonella and swine 
influenza virus, and evaluation of bacteriological and endoparasitic content of feces, is 
performed on serum, EDTA whole blood, and fecal samples by a commercial laboratory 
(Vaxxinova GmbH, Münster, Germany) employing their standardized ELISA- and PCR- based 
test systems. 
4 RESULTS 69 
 
 
2. 6 Peripheral blood mononuclear cell (PBMC) isolation and cultivation 
Porcine PBMCs were isolated by Ficoll gradient centrifugation (lymphocyte separation 
medium, PromoCell, Heidelberg, Germany), using Falcon tubes without porous barriers. The 
isolated PBMCs were washed and cultured in RPMI1640 medium supplemented with 10% fetal 
calf serum (FCS) (Merck Millipore, Darmstadt, Germany). DNA was isolated before and after 
incubation. 
 
2. 7 DNA extraction 
DNA was extracted from blood, purified PBMCs, nasal and oral swabs, or tissues using DNeasy 
Blood and Tissue kit (Qiagen GmbH, Hilden, Germany). DNA was quantified using a NanoDrop 
ND-1000 (Thermo Fisher Scientific Inc., Worcester, MA, USA). 
 
2. 8 Real-time PCR 
PCMV-specific real-time PCR testing was performed as described15,29,30 using specific primers 
PCMV real fw 5’ ACTTCGTCGCAGCTCATCTGA, PCMV real rev 5’ GTTCTGGGATTCCGAGGTTG,  
and PCMV probe FAM- 5’ CAGGGCGGCGGTCGAGCTC –BHQ15. To improve PCMV detection in 
blood or in purified PBMCs, PBMCs were incubated in culture medium previously shown to 
increase PCMV expression29 and PCR analysis was performed twice, before and after 
incubation of PBMCs in culture medium. Detection limit of the real-time PCR was two-to-five 
copies of PCMV and was performed using a SensiFast Probe No ROX One-step Kit, according 
to supplier recommendations (Bioline GmbH, Germany). Sixty ng of DNA was used for testing. 
The reaction mixture contained 400 nmol/L of both primers and 100 nmol/L of the probe in a  
final volume of 20 μL. The following conditions for amplification were used: denaturation at 
95°C for 5 minutes, 45 cycles of amplification with denaturation at 95°C for 10 seconds, 
annealing at 59°C for 20 seconds, and extension at 60°C for 25 seconds. Reporter fluorescence 
was measured using an Mx3005P Multiplex Quantitative PCR System (Stratagene, La Jolla, 
CA, USA). 
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3. RESULTS 
3.1 Establishment of the herd 
In this study, we aimed at establishing a PCMV-free breeding herd of gm pigs for 
xenotransplantation. Pregnant F0 sows were purchased from an external designated 
pathogen-free barrier facility and introduced into CiMM (Figure 1). CiMM was opened in 
December 2016 as a newly built pig barrier facility. Quarantine requirements of 48 hours  
without outside pig contact before entry are in place. Cleanroom showers are used, and a full 
change of clothes is performed upon entering the facility. Schönhammer ventilation system 
was installed (Schönhammer, Mengkofen, Germany) to discharge pollutants  and odors from 
the stable, target temperature stability and control humidity levels to prevent precipitation. 
F0 sows were the first pigs to enter this facility. In addition to PCMV screening, all animals 
were examined for the presence of the following pathogens on a serological and/or antigen 
basis: Serological testing was performed for Actinobacillus pleuropneumoniae, Haemophilus 
parasuis, Lawsonia intracellularis, Leptospira spp., Mycoplasma hyopneumoniae, Pasteurella 
multocida, porcine reproductive and respiratory syndrome virus, swine influenza virus, 
transmissible gastroenteritis, and hepatitis E virus. In addition, antigen testing took place for 
Brachyspira hyodysenteriae, Lawsonia intracellularis, salmonella and swine influenza virus, 
and fecal swabs were examined for bacteriological content and endoparasites. All testing is 
repeated continuously every 6 months on a representative proportion of the current pig 
population within CiMM to ensure adequate hygiene monitoring. To date, antigen detection 
of Brachyspira hyodysenteriae, Lawsonia intracellularis, and salmonella and swine influenza 
virus has remained negative. Serologically, the cohort is positive only for Actinobacillus 
pleuropneumoniae and Lawsonia intracellularis. 
 
3.2 Screening for and elimination of PCMV 
When testing for PCMV using a sensitive real- time PCR, seven of eleven F0 sows were at least 
once tested positive for PCMV (Table 1). Because of the premature death of sow 91107, no 
samples from this animal were available at the time of farrowing. When screening all 91 F1 
piglets born from the F0 founder sows, we found no PCMV- positive animal at any time point 
over the whole observation period of 14 months. Detailed results of repeated PCMV screens 
are depicted in Table S1. Two F1 animals were euthanized at the age of 4 months for collection 
of a full- organ set, one born from a PCMV- positive (#13) and the other born from a PCMV- 
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negative mother sow (#27). As control, an age- matched pig from a cohort without early 
weaning was used (#5157). Both piglets derived from the early weaning procedure were 
shown PCMV negative in all tested organs (Figure 3). 
Further, the gm offspring farrowed from the F1 PCMV-negative sows were tested for 
PCMV at one single time point, at which piglets were between 14 and 30 days old (Table 2). 
All 19 tested piglets were negative for PCMV, as were their respective mothers at the same 
time point. In addition, organ and blood samples were taken from stillborn, dead, or 
euthanized piglets and liver and spleen tissue was screened by real-time PCR for the presence 
of PCMV. All samples were tested negative, indicating the complete elimination of the virus 
from the breeding herd. 
 
4. DISCUSSION 
There is general consensus in the research community that potential donor animals must be 
free of PCMV if clinical xenotransplantation is to become reality. We present here the 
successful elimination of this virus from a complete breeding herd of gm pigs for biomedical 
research applications including xenotransplant donor animals. The pig population in this newly 
built and established research facility has remained free of detectable PCMV over the whole 
monitoring period of 14 months. This allows for the conventional breeding of experimental 
animals within the facility without having to employ measures such as isolated rearing of 
individual piglets as xenodonors. 
Determination of the PCMV status in this study has been made via PCR-based detection 
of the virus genome. For testing, PCR-based methods31 and immunologic methods detecting 
PCMV-specific antibodies32 can be used. Furthermore, screening for PCMV using non- 
invasively taken samples was found effective33. Even though antibody titers have been 
reported from piglets infected very early in life20, there is some evidence that no 
seroconversion takes place in piglets infected congenitally or neonatally34, making serological 
testing ineffective in cases where such infection routes are suspected. We thus chose to 
attempt direct virus detection to examine successful elimination of PCMV from the breeding 
herd. Because PCMV titers can be low or even close to the detection limit13, a PBMC culture 
system was established to promote virus replication and facilitate detection. As is 
demonstrated here, this cultivation step results in significantly higher virus titers in cells of 
animals that are positive for PCMV, reaching as far as providing positive results for animals 
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that on native blood samples had been below the detection limit (Table 1). Multiple testing of 
animals employing highly sensitive methods can thus be termed a necessity for confidently 
determining a PCMV-negative status within a pig cohort 
Other research groups have given account of PCMV elimination by early weaning in 
piglets destined as donors for pig-to-primate transplantations20-24. Tucker et al 35 report that 
not in all cases has it been possible to retain all animals free of PCMV. This has been attributed 
to the possibility of transplacental fetal PCMV infections, as postulated by Edington et al34 in 
1977. In this work, intrauterine transmission of PCMV could be detected in fetuses of 
serologically negative mother sows that had become infected during pregnancy. Today, it is 
common sense that intrauterine PCMV infection of fetuses can take place. However, to our 
knowledge, there are no definitive reports of transplacental PCMV transmission to fetuses 
aside from experimentally induced infection in previously seronegative sows. While there 
seems to be indeed the chance of opportunistic infection due to first contact of sows with the 
virus during pregnancy, this appears not to be the case often. Moreover, piglets infected 
congenitally are usually weak and die within weeks of birth21. Consequently, early weaning 
programs for elimination of PCMV might more likely fail by accidental transmission of 
infectious material between different cohorts of isolated pigs through caretaker or research 
personnel than by congenital transmission of the virus. Our own findings of an albeit rather 
low number of PCMV-positive sows that nevertheless all gave birth to completely PCMV- 
negative offspring, support this notion. However, the incidence of inadvertent PCMV 
infections during previous attempts of generating PCMV-negative xenograft donors highlights 
the importance of barrier facilities completely devoid of the virus. 
As PCMV is distributed by oronasal secretions and consequently airborne infection36, 
all contact with potentially infectious discharge and aerosols must be avoided if transmiss ion 
is to be excluded. That results in immense effort on the side of personnel coming into contact 
with the animals. Great care has to be taken when switching from one animal or animal cohort 
to the next. Typically, barrier animal housing facilities require individuals accessing the facility 
to follow some kind of quarantine procedure (eg, no contact to animals of the same species 
outside the facility within the past 48 hours) in addition to showering and complete change of 
clothes upon entering. Something similar would have to be employed within the facility if strict 
separation of individual pigs for infection protection is to be performed adequately, thus 
requiring such man power as can only be provided at enormous costs. PCMV sanitation of a 
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complete facility offers the great benefit of having to undertake complicated isolation 
measures only once as opposed to repeatedly protecting specific animals from PCMV infection 
by early weaning and rearing in isolators. 
Finally, developments in recent years have shown that legislation concerning animal 
welfare has become ever stricter. This can surely be attributed to an increased perception of 
such issues within modern Western society that is not willing to tolerate unnecessary strain 
on experimental animals. The pig as a sociable animal falls under great stress if separated from 
its peers37. Isolation husbandry can thus already only be employed in exceptional cases, and 
the assessment of such cases is likely to become even more severe in the future. This is 
especially true if the procedure not only demands avoidance of direct physical contact 
between animals but also requires protection from the air space of other animals, meaning 
that it is difficult, if not impossible, to at least allow for visual and audio contact between pigs. 
By eliminating PCMV completely from a whole pig research facility and thus allowing 
for animal production by conventional breeding, the grounds for regularly supplying 
xenotransplant donors have been strengthened. The cohort of xenopigs presented here may 
be utilized as a basis for deeper examination of their status regarding known and emerging 
infectious agents and subsequently improving the herd toward a supply chain for clinical 
xenotransplantation. 
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TABLE 1 PCMV screen of 11 Fehmarn mother sows 
 
 
Time point PPDa -28 PPD 0  PPD 0 
Sample Blood 
Nasal 
swab 
Blood 
PBMCs 5 d 
cultivation 
PBMCs 7 d 
cultivation 
#89030 –b +c – – – 
#91106 + + +d + ++ + + 
#91107 – n.d.e n.d. n.d. n.d. 
#91108 + + – – + + + + 
#91111 – – + + + + + 
#91112 – – – – – 
#91114 – – – – – 
#91117 + – – + + 
#91118 – – – – – 
#91119 – + + + + + + 
#91122 + – – – + 
aPostpartal day.     
bNegative result.     
cPositive result.     
dStrongly positive result.     
eNot determined.     
 
All eleven DanAvl hybrid sows purchased from the barrier facility on Fehmarn were tested for 
PCMV 28 d prior to (PPD – 28) and 1d after farrowing (PPD 0) using sensitive real-time PCR. 
Seven of eleven F0 sows were tested positive for PCMV at least once. Because of the 
premature death of sow 91107, no samples from this animal were available at the time of 
farrowing. PBMC isolation and cultivation was performed from PPD 0 lithium heparin whole 
blood. PBMC cultivation increases virus production and detectability of PCMV. 
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TABLE 2 PCMV screen of genetically modified offspring 
 
 
#10001 79 Oct 30, 2017 30 d –b 
#10002 
#10003 
#10004 
  30 d 
30 d 
30 d 
– 
– 
– 
#10005 
#10006 
#10007 
50 Nov 7, 2017 22 d 
22 d 
22 d 
– 
– 
– 
#10008 70 Nov 8, 2017 21 d – 
#10010 
#10011 
#10013 
52 Nov 8, 2017 21 d 
21 d 
21 d 
– 
– 
– 
#10022 
#10023 
#10024 
#10026 
#10027 
42 Nov 14, 2017 15 d 
15 d 
15 d 
15 d 
15 d 
– 
– 
– 
– 
– 
#10032 
#10034 
#10037 
43 Nov 15, 2017 14 d 
14 d 
14 d 
– 
– 
– 
aAll piglets were sampled Nov 28, 2017. 
bNegative result. 
 
Nineteen genetically modified offspring animals aged between 14 and 30 d and their 
respective F1- generation mother sows were tested negative for PCMV on cultivated PBMCs. 
Pig Mother sow Day of litter Age of pigleta PCMV 
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FIGURE 1 Establishment of CiMM. Eight pregnant PCMV-positive and 3 pregnant PCMV- 
negative DanAvl hybrid sows (F0) were purchased from a DPF barrier facility on the island of 
Fehmarn (1) and transferred to the newly established CiMM 4 wk prior to their farrowing 
date (2). Offspring (F1 generation) and sows were separated immediately after birth, and 
piglets were allowed to suckle colostrum under controlled conditions every 2 h for 24 h 
postpartum (3). Piglets were then transferred to a Rescue Deck system with milk replacer 
feeding, and sows were removed from the facility (4). F1 piglets were screened periodically 
for PCMV over a total period of 14 mo (5) and raised to serve as recipients for gm embryos 
(6). 
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FIGURE 2 Establishment of PCMV negative xenograft donor herd. In vitro fertilization (IVF) 
was performed using in vitro matured (IVM) oocytes collected from slaughterhouse material. 
Genetically modified (gm) epididymal sperm collected from gm boars was used to fertilize 
the IVM oocytes. After fertilization, cumulus cells  and excess sperm were removed and only 
oocytes with one or two visible polar bodies were used for embryo transfer to estrus - 
synchronized PCMV-negative F1 sows. For somatic cell nuclear transfer (SCNT), porcine 
oocytes were enucleated and gm porcine primary cells were injected into enucleated 
oocytes. After electric fusion and activation, embryos were transferred into the oviducts of 
estrus- synchronized PCMV-negative F1 sows. 
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FIGURE 3 PCMV is eliminated from all organs of early weaned piglets. 
Organ sets from two F1 animals were tested for PCMV. Piglet #13 was born from a PCMV- 
positive F0 mother sow, and piglet #27 was born from a PCMV-negative F0 mother sow. 
Both animals are negative for PCMV in all tested organs with zero copy numbers of PCMV 
detectable. Animal #5157 raised without early weaning in standard agricultural environment 
is clearly PCMV positive, with the highest copy numbers in liver tissue. Quantities are 
depicted as virus genome copy numbers per cell. 
 
 
 
“Copyright 2018 Wiley. Used with the permission from Stefanie Egerer, Uwe Fiebig, Barbara 
Kessler, Valeri Zakhartchenko, Mayuko Kurome, Bruno Reichart, Christian Kupatt, Nikolai 
Klymiuk, Eckhard Wolf, Joachim Denner and Andrea Bähr, Early weaning completely 
eliminates porcine cytomegalovirus from a newly established pig donor facility for 
xenotransplantation and Wiley / Xenotransplantation.” 
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4.2 Consistent success in life-supporting porcine cardiac 
xenotransplantation 
This article documents the long-time survival of baboon xenograft recipients after receiving a 
fully life-supporting heart from donor pigs that were raised and maintained at the Chair of 
Molecular Animals Breeding and Biotechnology (LANGIN et al., 2018). After decade-long 
struggling with orthotopic heart transplantations, three factors finally led to the success with 
the pig-to-primate xenotransplantation model. First, the genetic constellation of 
GTKO.hCD46.hTBM generated at the Chair for Molecular Animal Breeding and Biotechnology 
is obviously a simple but optimal basis for preventing antibody-mediated rejection and 
microthrombosis (MOHIUDDIN et al., 2016; SINGH et al., 2019). Second, the switch from the 
cold ischemic preservation (static preservation with 4°C cold crystalloid solutions, e.g. 
Custodiol®) to the non-ischemic preservation method developed by Steen et al. (STEEN et al., 
2016) improved the weaning of the recipient baboons from the cardiopulmonary-bypass 
(CPB). Finally, another vital factor was the inhibition of the growth of the pigs’ hearts in the 
recipients by a trinomial therapy approach: antihypertensive treatment for the baboons to 
match the blood pressure of the pigs, earlier weaning of cortisone and treatment with 
temsirolimus, the prodrug of sirolimus to attenuate heart overgrowth (LANGIN et al., 2018). 
My contribution to this work was the veterinary herd management of the pigs, the planning 
and scheduling of matings, the genotyping of offspring and the supply of healthy animals to 
the Walter-Brendel-Center for Experimental Surgery. The finally approved manuscript can be 
found at Nature. 2018 Dec;564(7736):430-433. doi: 10.1038/s41586-018-0765-z. 
https://www.nature.com/articles/s41586-018-0765-z 
 
 
 
 
4.3 Targeting αGal epitopes for multi-species embryo immunosurgery 
 
In this paper we investigated whether serum of GTKO pigs is a sufficient and reliable source of 
anti-Gal antibodies for inducing complement-mediated lysis of the trophectoderm cells. In 
previous attempts, immuno-surgery had proven potential by first coating the trophectoderm 
with antibodies and second by lysing the trophectoderm by the complement system via the 
classical, antibody-mediated complement activating pathway. Blood serum should normally 
provide both, the antibodies against the embryo and the complement components. The 
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efficacy of the process, however, was unstable, depending on the serum used. The idea behind 
our approach was that most mammalian species carry αGal epitopes, whereas the few species 
that lack these epitopes develop high levels of antibodies against αGal as a result of 
permanent stimulation by αGal-carrying bacteria. Thus, it was evident to test the potential of 
serum from αGal-lacking individuals in immunosurgery. As GTKO animals have been 
developed at the Chair of Molecular Animal Breeding and Biotechnology, it was tempting to 
use their serum in such an approach. In the study, it was first examined, if the four mammalian 
species used in the study, mouse, rabbit, cattle and pig had αGal epitopes on their blastocysts, 
as it was only known for pig embryos, that αGal epitopes appear first at the 8-cell stage (CHI 
et al., 2012). Then, the αGal-antibody levels were determined in different GTKO animals. 
Finally, the concept of immunosurgery was confirmed by treating embryos from all three 
species with GTKO serum. With this approach the inner cell masses of blastocysts from all 
species could be isolated and though they were exposed to the complement s erum before 
lysis, they showed satisfactory levels of purity. My contribution to this work was sampling of 
blood, preparation of serum, undertaking sections of the GTKO animals and preparation of 
samples for immunohistochemistry (IHC). The finally approved manuscript can be found at 
Reprod Fertil Dev. 2019 Apr;31(4):820-826. doi: 10.1071/RD18120. 
https://www.publish.csiro.au/RD/RD18120 
 
 
 
 
4.4 Transmission of porcine circovirus 3 (PCV3) by xenotransplantation of pig 
hearts into baboons 
This manuscript described the first trans-species transmission of PCV3, as well as the 
abundance of PCV3 in our breeding herd. Due to its mild and ambiguous clinical course, PCV3 
has been detected in pig herds only recently, but in the meanwhile, it turned out that the virus 
is pandemic in a significant proportion of herds all over the world. Evidently, it has been found 
in our existing xenotransplantation donor herd at LVG. In the xenotransplantation context it 
is important to consider that we here document the transmission of PCV3 to four baboons 
after transplantation of a heart from an infected donor pig. As PCV3 was found in all organs 
of the baboons, with even more virus load the longer the survival time of the baboon was, an 
active replication of the virus in the transplant and/or the recipient can be suggested. My 
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contribution was providing frequent blood samples of the pigs and coordination of sample 
analysis, as I could specify where exactly the animals were and so help investigation and 
discuss possible transmission and infection routes of PCV3 in our herd. Further investigations 
on the PCV3 transmission in our herd and further infection trials are currently ongoing. The 
approved manuscript can be found at Viruses. 2019 Jul 16;11(7). pii: E650. doi: 
10.3390/v11070650. 
https://www.mdpi.com/1999-4915/11/7/650 
 
4.5Inheritance of porcine endogenous proviruses in the xenotransplantation 
breeding herd at MABB 
One of the most critical characteristics of xenotransplantation donor animals is their status of 
PERV, particularly PERV-C. Ideally donor pigs should be free of PERV-C (DENNER et al., 2009). 
For clarifying the occupancy of the genomes of our xenotransplantation donor pig breeding 
herd, we followed two different strategies. 
First, the porcine reference genome was examined for the PERV-A, -B and -C subfamilies. In 
total 24 PERV-A and 18 PERV-B were identified on the basis of their env gene sequences, but 
no PERV-C env was identified. On the basis of LTR-sequences, however, 69 PERV-A, 98 PERV- 
B and 25 PERV-C elements were found. Not all proviral-like structures contained a full provirus, 
rather they were regularly disrupted by larger gaps within the provirus or at one of their ends. 
In the latter case, they comprise only one single LTR and a determination of their age, based 
on the differences between the up- and downstream elements is not anymore possible. 
Unrooted phylogeny PERV LTR elements show a clear separation of the A-, B- and C- 
subfamilies (Figure 2). All up- and downstream pairs of LTR of given proviruses fall into the 
very same cluster. An interesting side-finding was that all proviruses with LTR clustering to the 
A-subfamily contained an env sequence similar or identical to the commonly used PERV-A 
reference virus (GenBank annotation AJ253656). In contrast, proviruses with LTR clustering to 
the B-subfamily) contained either env sequences similar or identical to the commonly used 
PERV B reference virus (GenBank no. AJ253657) or PERV-A env. 
Most important for the PERV-C subfamily, however, was that many LTR clustered with the 
PERV-C reference virus (GenBank no. AF038600), but those comprised either solo-LTR or, 
4 RESULTS 85 
 
 
surprisingly, proviruses that lack large parts of the env gene. Thus, none of the proviruses in 
the SusScrofa reference genome 11.1 constituted a tropism of PERV-C. 
 
 
 
 
 
Figure 2 Phylogeny of PERV from the pig reference genome SusScrofa 11.1. LTR sequences 
were extracted from the genome and aligned. The tree is based on a maximum likelihood tree, 
with branches occurring also in most parsimony depicted in bold and branch nodes that 
occurred more often in 70 out of 100 genetic distance trees indicated. For better resolution, 
the solo-LTR are not indicated by name, but pairs of LTR that flank a provirus are given by their 
chromosomal position, the differences between the two LTR and the characterization of the 
sub-family based on the env genes. For better indication, proviruses with env of the PERV-A 
are marked in green, PERV-B is marked in magenta and PERV-C is marked in blue. If one end 
of the provirus has been affected by large genomic deletions, the difference of LTR cannot be 
determined (“nd”). If the sequence quality of the env gene was improper it is indicated by a 
“?” and if the env gene is affected by larger deletions the env gene is unknown (“-“). In both 
cases, the proviruses are marked in grey. (analysis done by N. Klymiuk) 
4 RESULTS 86 
 
 
In the second attempt, PERV-C proviruses were identified by Targeted Locus Amplification 
(TLA) sequencing (DE VREE et al., 2014) on a commercial basis by Cergentis (Cergentis, Utrecht, 
the Netherlands). The load of PERV-C was determined in four different individuals (pig number 
1476, 3990, 4504 and 4686) from our breeding herd (Figure 3). In total, 11 proviruses of PERV- 
C have been identified and sequenced and specific PCRs for each integration site have been 
established by I.Kola during the preparation of her doctoral thesis “Deleting PERV-C infectious 
potential of donor pigs for xenotransplantation”. 
 
 
Figure 3 PERV-C identified in 4 genetically modified pigs from LMU, data provided by 
Cergentis, Utrecht, the Netherlands. 
 
 
Based on the striking difference of PERV-C abundance in the reference genome versus four of 
our multi-modified piglets, the phylogenetic relationship between any LTR clustering with the 
PERV-C reference AF038600 was determined (Figure 4). Based on phylogenetic trees there is 
a clear separation of PERV-C LTR from the references of A, B. Although all PERV-C sequences 
appear highly homologous, there is a further clustering of the almost identical reference 
sequence, all PERV-C identified by TLA sequencing and the provirus remnant at 
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chr14:62.55Mb. The other LTR form a more diverse cluster, characterized by an ambiguous 
pattern of polymorphic sites and a significant number of unique positions. This interpretation 
of a highly homologous sub-cluster and a more diverse group is also supported by principle- 
component analysis. 
 
 
 
 
 
 
Figure 4 Analysis of LTR clustering with the reference PERV-C AF038600. A phylogenetic tree 
was generated according to the procedure described in Fig. 2 and rooted with LTR from the 
reference viruses of PERV-A and B (left panel). Designation of the LTR was done according 
their integration in the reference genome. Proviral sequences were designated as “C”, if the 
env was corresponding to the reference virus (blue) and “-“ if the env was largely lacking 
(grey). If both LTR of a provirus were entirely abundant, the difference between them is 
indicated versus their length. A position-wise comparison of the polymorphic sites in the 
alignment of all LTR is given in the middle panel. All positions identical to the reference virus 
are in blue whereas deviations occurring in more than a single sequence are given in pale. 
Differences that occur only in a single sequence are removed from the alignment and the 
numbers of such unique positions are given for each sequence in columns. Finally, principle 
component analysis of the alignment was performed by Jalview (right panel) and the clusters 
identified are correlated to the other two methods. (analysis done by N.Klymiuk) 
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The finding of two different clusters within PERV-C LTR was not really surprising, when one 
considers, that on one hand a group of proviruses lacking large parts of the env C has been 
found in the reference genome, whereas another group of largely intact proviruses has been 
identified by TLA sequencing. Surprisingly, however, one of the disrupted proviruses, 
chr14:62.55Mb strongly groups with the intact PERV-C whereas the other cluster showed a 
much higher diversity. It is important to consider that this higher divergence did not clearly 
support the assumption of an older age of this cluster, because differences between up- and 
down-stream LTR are relatively low. Still, based on this data set, one might come to the 
conclusion that the full PERV-C have appeared in the genome more recently, and it appears 
that they have come in at once, whereas the truncated PERV-C have populated the porcine 
genome during a longer period of time. Considering the impotence of these proviruses to 
spread in the genome on their own competence, the main question was then, by which way 
these proviruses have integrated in the pig genome. As proviral integration of gamma 
retroviruses results in a typical duplication of 4bp at the integration site due to integrase 
activity, I clarified the flanking sequences of the proviruses chr.14:62.55, chr.11:29.09, 
chr.2:0.23 and scf141. Consistently, all four integration sites revealed identical 4bp sections 
up- and downstream of the provirus, but the 4bp sections differed between each provirus 
(Figure 5). This finding matched the analysis of the 11 intact PERV-C, which has been 
performed previously by I.Kola (Figure 6). Other PERV-C proviruses either lacked one of their 
terminal ends, or were embedded in highly repetitive genomic regions, which prevented the 
independent amplification of the proviral ends. Taken together, this analysis shows that the 
truncated PERV-C are rather the product of integrase-mediated colonization of the genome, 
than a product of transposon-mediated accumulation or the product of pseudogene-like 
reverse transcription. 
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Figure 5 Flanking regions of the truncated PERV-C-like proviruses. The transitions from the 
provirus (capital letters) into the adjacent genomic region (small letters) is indicated for the 
proviruses at chr14:62.55, chr11:29.09, chr2:0.23 and scf141. The intimately adjacent 
positions are underlined and depicted in bold. The structure for each provirus is given 
schematically, with the positions and lengths of larger deletions indicated. At the very right, 
mismatches between LTR are shown. 
 
 
 
 
Figure 6 Flanking regions and 4 bp duplications of the 11 PERV-C proviruses identified by 
I.Kola. 
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As both, the intact PERV-C, as well as the disrupted proviruses appear to be the product of 
retroviral integration, we followed their pattern of inheritance throughout the history of our 
xenotransplantation donor herd. Each of a total of 148 animals was examined for the 
abundance of 11 PERV-C proviruses and 3 proviral remnants (Table 13 and Table 14). Basically, 
it appeared that none of the animals had all of the proviruses in their genome and none of the 
proviruses appeared in all of the animals. In more detail, it became evident that any proviral 
integration was inherited to the offspring in a strictly Mendelian pattern throughout 8 
generations of breeding (Figure 7). Following the stochastical principles behind inheritance 
and the relatively strong inbreeding within our donor herd, it was not surprising that some of 
the proviruses were lost by time, whereas others increased in their frequency within the herd 
as long as no attention was paid to the PERV-C-population, when animals were selected for 
breeding. After identification of the integration sites, breeding animals were selected for their 
PERV-C load, and a slow decrease of PERV-C in the herd has been achieved in the meanwhile. 
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Figure 7 Inheritance of proviral sites in the xenotransplantation donor herd. The breeding 
history started by mating a cloned GTKO.hCD46 boar (Rev) with HLAE-transgenic sows. Later 
on, boars being transgenic for hTBM or INS-LEA (bLEA) were introduced into the mating 
scheme. For the ease of understanding, the genetic constellation of the animals is not 
indicated. Circles symbolize sows and boxes represent boars. Individuals that have been used 
for TLA-sequencing are depicted in magenta; individuals that are entirely free of PERV-C env 
are highlighted in light blue. The inheritance pattern of proviruses at specific nodes and for 
selected integration sites (marked by capital letters) is shown in separate tables.  
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5 Discussion 
 
My working on the maintenance and sanitation of the LMU´s breeding herds for 
xenotransplantation, the veterinary management of the animals, as well as the providing of 
animals, tissue, or blood samples to different research projects allowed the contribution to 
distinct studies and facilitated insight into different aspects of xenotransplantation, ranging 
from hygiene aspects to preclinical research and molecular details of antibody-mediated 
complement activation. 
 
 
 
5.1 Perspectives of xenotransplantation in comparison to alternatives 
 
As a result of the enormous relevance of life-threatening heart diseases, in particular in the 
Western World, tremendous efforts are being undertaken in providing treatments to human 
patients. Evidently, many more attempts than xenotransplantation are being considered, and 
some of them are clinically used. Maybe the most widely used are left (or biventricular) assist 
devices (KIRKLIN, 2014; PATEL et al., 2014; KIRKLIN et al., 2015), which have been initially 
inserted as a bridge-to-transplant support, but the devices are increasingly used, also as 
destination therapy, implying that no allotransplant will be carried out (reviewed in MOU et 
al., 2015). An unfortunate complication of mechanical assist devices is very often sensitization 
to human leucocyte antigens (HLA) antigens, as a consequence of the multiple blood 
transfusions needed during the process. This normally exacerbates the search for a fitting 
deceased donor heart and compromises the value of mechanical assist devices as bridging 
therapy (COOPER & TEUTEBERG, 2010). The total artificial heart (TAH) is another, or, in many 
cases, the last option for those patients, who cannot be rescued by assist devices alone 
(COPELAND et al., 2012) or when allografts fail (QUADER et al., 2013). However, TAHs have 
their limitations due to limited durability (in average less than 5 years) (reviewed in GOERLICH 
et al., 2016) and impairment of their users’ well-being and comfort with their sizeable external 
parts and noisy, large pump (SUNAGAWA et al., 2016). 
A popular approach for treating many diseases is the application of pluripotent stem cells 
(PSCs) (CARPENTER et al., 2009; FOX et al., 2014). Basically, there are three categories of stem 
cells: first, there are permanent stem cells in most mature tissues with high turn-over rates, 
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which are responsible of taking care of tissue preservation. Then embryonic stem cells from 
culture of preimplantation embryos, which are seen as pluripotent, as they can differentiate 
in any cells existing in the human body. And lastly reprogrammed adult cells, referred to as 
induced PSCs (iPSCs) (reviewed in LANE et al., 2014). The PSCs can be obtained by 
manipulating the stem cell microenvironment, or “niche”, to facilitate repair by endogenous 
stem cells (reviewed in LANE et al., 2014). The niche was first described by R. Schofield in 1978 
(SCHOFIELD, 1978) as hypothetical interaction of stem cells and their environmental cells. 
There are niches in many tissues, for example in skin (FUCHS, 2009), intestines (BARKER, 2014; 
TAN & BARKER, 2014), and the nervous system (CONOVER & NOTTI, 2008). Regarding the 
heart or the myocardial tissue, it was shown, that PSCs can differentiate into cardiomyocytes 
in animal models (LAFLAMME et al., 2007; XIONG et al., 2013). Improvement of the function 
of infarcted hearts, that were transplanted with mouse and guinea pig PSC-derived cardiac 
progenitors (SHIBA et al., 2012) and even long-term benefit has been reported in the repair of 
a damaged heart (HARRIS et al., 2007; SCHOLL et al., 2010). Importantly, induced PSCs proved 
as an innovative and attractive source of PSCs, simply generated from differentiated cells by 
somatic cell reprogramming (TAKAHASHI & YAMANAKA, 2006). Still, in many cases organs are 
so severely damaged that cellular regeneration is believed to be of little use and replacement 
by a “new” heart is the only chance to save patients´ lives (reviewed in MOU et al., 2015). 
On the other hand, the availability of personalized, autologous iPSC, stimulated also the field 
of tissue engineering (reviewed in BERTHIAUME et al., 2011). The term tissue engineering 
comprises living cells, biocompatible materials and suitable biochemical factors for creating 
tissue-like structures. State-of-the-art approaches use scaffolds made from naturally derived 
and synthetic polymers, bioresorbable inorganic materials, hybrids, or decellularized tissue 
scaffolds (reviewed in PINA et al., 2019), which are then cellularized either with iPSCs or donor 
cells. This was done, for example with rat kidneys and discarded human transplant kidneys, 
using human inducible pluripotent stem cell–derived endothelial cells for re‐ 
endothelialization (LEUNING et al., 2019). This may be a possible application in the future, but, 
as the heart is a very complex organ and consisting of multiple cell types, with various 
functions, an appropriate multi-cellular composition, which resembles the heart does not exist 
until now (OWEN & HARDING, 2019). 
Another development in the growing field of tissue regeneration is blastocyst 
complementation (CHEN et al., 1993). The generation of a whole functioning human organ, 
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solely derived by the patient’s iPSCs is the ultimate goal, as it would significantly reduce the 
immune response (reviewed in MOU et al., 2015; reviewed in OLDANI et al., 2017). The basic 
idea is that organs are formed, by cells from a complementary individual, if a developmental 
niche is provided by the host. Concept was proven when mouse iPSC-derived kidneys were 
generated in mice (USUI et al., 2012). In a further study, cross -species chimeras were 
generated, when rat-derived iPSCs formed the pancreas in mice (KOBAYASHI et al., 2010). 
Later it was shown, that the blastocyst complementation technique can be applied to the pig 
(MATSUNARI et al., 2013). Further, human-pig chimeras were reported at embryonic stage 
(WU & IZPISUA BELMONTE, 2015; WU et al., 2017), but the experiments were not carried out 
until birth. Thus, the viability of such individuals remains elusive and the practicable terms of 
this approach are unclear. Very importantly, the concept of blastocyst complementation has 
also raised significant ethical concerns (HERMERÉN, 2015; SHAW et al., 2015). 
The latest innovation in the expanding field of bioengineering is 3D tissue printing (reviewed 
in MURPHY & ATALA, 2014). As the used technologies for 3D printing were originally not 
intended for the use with biological materials, the first printers used for bioprinting were 
modified, commercially available, ink-based printers (XU et al., 2008) and the selection of the 
materials is one major task. Not only do they have to withstand the printing process, but they 
should supply the wanted characteristics for the tissue to be composed. Only recently a proof- 
of-concept study was performed where contractile cardiac tissue constructs were printed, 
which were able to perform synchronal contractions (WANG et al., 2018). Additionally, two 
very promising studies printed human “hearts”. One printed small-scale human hearts, as a 
proof-of-concept, that anatomical, volumetric and complex structures can be printed, using a 
personalized hydrogel as matrix (NOOR et al., 2019) and the other group was able to directly 
print collagen and thus bioengineer tissue parts of the human heart at various sizes and even 
a neonatal-sized human heart (LEE et al., 2019). Though these are very encouraging results, 
the 3D bioprinting technology still needs to overcome significant obstacles, like the generation 
of countless millions of cells needed to print large tissues or the creation of a feasible workflow 
for clinical adaption and still the most challenging, is the creation of a fully functional 3D bio 
printed organ. 
In the context of many promising, but not yet clinically applicable approaches, the recent 
publication of consistent long-term survival of xenotransplanted pig hearts in primates  for up 
to 6 months resembles a major breakthrough (LANGIN et al., 2018). Not only would pig  
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breeding facilitate the regular, reliable, and continuous production of donor individuals, but 
also allow a much better planning of transplantation events and the application of techniques, 
that are well established in the course of allotransplantation. Importantly, the physiological 
function of a pig heart is apparently life-supporting in a living primate, a fact that has not been 
yet proven for any of the above described biological replacements. Some aspects such as the 
controlling of the pig heart´s intrinsic growth potential need definitely further consideration, 
but the induction of a genetically induced dwarfism in the donor pigs (HINRICHS et al., 2018) 
might be a sufficient approach to tailor the size of the donor pigs. Similarly, the so far 
significant immunosuppressive burden might be decreased, when local T-cell control is 
induced, such as by the expression of PDL1 (BUERMANN et al., 2018) or by the secretion of 
LEA29Y (BAHR et al., 2016). The most critical point of supplying donor animals for 
xenotransplantation, however, is the threat of transmitting pathogens from the donor to the 
recipient, and, if becoming pandemic, among the human population. Therefore, a strict 
hygiene standard of the donor pig is necessary and the exemplified sanitation of the hygiene 
status in a donor herd was the core of my thesis. 
 
5.2 The way towards an approved barrier facility for clinical trials 
 
It is important to mention, that so far, no specific regulations exist that describe the 
maintenance of donor pigs for xenotransplantation, rather there are only recommendations 
or guides, most notably in the context of clinical trials. Most of the guidelines published by 
WHO, FDA or EMA deal with more general considerations, such as standards for facility 
construction or the importance of keeping notes about feeding, water supply, deposition of 
waste and so on. As such, the “Guidance for Industry: Source Animal, Product, Preclinical, and 
Clinical Issues Concerning the Use of Xenotransplantation Products in Humans” (FDA, 2003) 
claims, for example, that barrier facilities should be built, accredited by the AAALAC and run 
in accordance with the “Guide for the Care and Use of Laboratory Animals” from the National 
Research Council (NRC, 2011). Being claimed as the “Gold Standard” of laboratory animal care 
(SPIZZO et al., 2016) the “Guide for the Care and Use of Laboratory Animals”, is, however, 
rather written for specialized mouse or small rodent barrier facilities, so that only the basic 
principles defining documentation, training of employees, veterinary care, etc. are helpful. On 
the other hand, the “Guide for the Care and Use of Agricultural Animals in Research and 
Teaching” by the Federation of Animal Science Societies (FASS) (FASS, January 2010) gives 
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more specific advice for keeping pigs as an agricultural animal. But the guide has been mainly 
written for the use of large animals in e.g. field research for agricultural purposes or teaching. 
Although it has been updated, only little information is given on the specific demands in 
biomedical research, and therefore the described standards of biosecurity, SOPs, veterinary 
practice and GMP standards are helpful for general maintenance principles, but they do clearly 
not fully cover the demands of donor pigs for xenotransplantation. 
One obviously critical point of housing donor pigs for xenotransplantation will be the 
regulation of access to the pigs. It is well known, that the number of individuals entering the 
facility and the frequency of entry must be minimized. At least a complete documentation of 
external people visiting the facility should be kept. Therefore, we installed a sort of 
“Guestbook” at the entry of CiMM where every guest, external technician and member of any 
other workgroup have to declare, that he/she had no contact to pigs for at least 2 days and 
that he/she is not ill at the moment or was not ill in the past days. Furthermore, he/she 
declares his/her agreement with the use of the double door changing system, including the 
use of the shower and the change of clothes included in this system. A further 
recommendation from the “Guidance for Industry: Source Animal, Product, Preclinical, and 
Clinical Issues Concerning the Use of Xenotransplantation Products in Humans” by the Food 
and Drug Administration (FDA, 2003) proposes to even limit the traffic of caretakers between 
distinct compartments of the facility or between different groups of animals. Working with 
more than one herd on a single day should only be done if validated SOPs for disinfection and 
decontamination are employed. This regulation, however, cannot be executed at CiMM at the 
present timepoint, because this is only possible at very high personal and monetary expense. 
Surprisingly, European regulations, so far, consider only the production of cellular 
xenotransplantation products in the clinical xenotransplantation context, the so-called 
Advanced Therapy Medicinal Product (ATMP), and in detail describe requirements for 
isolation, treatment and cultivation of those products, based on the EU Regulation 1394/2007 
(PARLIAMENT, 2007) (reviewed in SCHUURMAN, 2015). Unfortunately, this regulation is, 
coincidentally with any other regulations, not very informative on the requirements under 
which donor animals should to be kept. In very common and general terms regulatory 
authorities like WHO (WHO, 1998), EMA (EMA, January 1, 2010) or FDA (FDA, 2003) claim, 
that the test regimen should be tailored to the purpose of the animals’ use, the test regimen 
should be established in accordance with experts from the fields of veterinary medicine, 
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virology and epidemiology and thus, the established regimen should be reviewed at given 
timepoints to keep it up with the advance of scientific knowledge. It is, however, evident that 
there are a lot of different opinions on these scientific considerations, and there is little to no 
consensus of an adequate and feasible hygiene monitoring. With a certain reputation, the 
International Xenotransplantation Association (IXA) has made recommendations which are 
extremely extensive, covering more or less any pathogen that has been associated with pig  at 
any time (SCHUURMAN, 2009). Meanwhile, their current version “First update of the 
International Xenotransplantation Association consensus statement on conditions for 
undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 2a: source pigs- 
-preventing xenozoonoses.” (SPIZZO et al., 2016) condensed this initially proposed test 
regimen to a more practicable extent. Other authors aimed at the same purpose and 
published their personal suggestion of test regimen (GARKAVENKO et al., 2004a; 
GARKAVENKO et al., 2008a; WYNYARD et al., 2014; FISHMAN, 2018). Regarding bacteria and 
viruses there is certain coincidence between these studies and the updated IXA consensus 
statement, whereas the agreement is less pronounced regarding fungi or protozoa (Table 11). 
 
 
 
 
Fishman 
2018 
Spizzio 2016 
(IXA) 
Wynyard 
2014 
New Zealand 
Garkavenko 
2004+2008 
 
CiMM 
Bacteria      
Leptospira 
Serovar Tarrasovi 
  
  
Leptospira 
Serovar Hardjo 
  
  
Leptospira Serovar 
Pomona 
  
  
Leptospira 
interrogans 
    

Mycoplasma 
hyopneumoniae 
  
 

Campylobacter 
  
  
Yersinia      
E.coli K88      
Salmonella spp.     
Mycobacterium 
tuberculosis 

    
Shigella      
nontuberculous 
mycobacteria 

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+ M.bovis      
Listeria 
monocytogenes 

    
Brachyspira 
hyodysenteriae 
/pilosicoli 
     

Lawsonia 
intracellularis 
    

Pasteurella 
multocida 
    

Actinobacillus 
pleuropneumoniae 
    

C. perfringens     
Haemophilus 
parasuis 
    

bact. pool 
examination from 
feces 
     

Brucella suis      
      
Viruses      
MRV      
HERV-K      
PCV2      
PCV1      
PLHV      
PLHV2      
PCMV     
Rotavirus A-C     
Reovirus      
PTV      
PEVB      
PHEV      
HEV     
BVD      
SuHV-1 (AujD)      
PPV      
PRRSV     
EMCV      
PERV     
Adenovirus      
Rabies virus      
TGEV     
Influenza virus 
(human) 

    
Influenza virus 
(swine) 

   

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Protozoa/ 
Parasites 
     
Toxoplasma gondii      
Ascaris suum      
Cryptosporidium/ 
Microsporidium 
spp. 
 

 

 

  
Echinococcus spp.      
Giardia spp.      
Isospora sp.      
Strongyloides sp.      
Trichinella spiralis      
endoparasites 
(flotation and 
sedimentation) 
     

Trypanosoma spp.      
      
Fungi      
Aspergillus sp.      
Candida sp.      
Cryptococcus 
neoformans 

    
Histoplasma 
capsulatum 

    
 
 
Table 11 Proposed test regimens adapted from different authors (GARKAVENKO et al., 2004a; 
GARKAVENKO et al., 2008a; WYNYARD et al., 2014; FISHMAN, 2018) and IXA (SPIZZO et al., 
2016) compared to the test regimen of CiMM. (refer to Table 1) 
(MRV: mammalian orthoreovirus, HERV-K: Human endogenous retrovirus K, PCV1 /2: porcine circovirus 1/2, 
PLHV: porcine lymphotropic herpesvirus, PLHV2: porcine lymphotropic herpesvirus 2, PCMV: porcine 
cytomegalovirus, PTV: porcine teschovirus, PEVB: porcine enterovirus, PHEV: porcine hemagglutinating 
encephalomyelitis virus, HEV: hepatitis E virus, BVD: bovine virus diarrhea, SuHV-1 /AujD: suid alphaherpesvirus 
1/ Aujezsky’s disease, PPV: porcine parvovirus, PRRSV: porc ine reproductive and respiratory syndrome virus, 
EMCV: encephalomyocarditis virus, PERV: porcine endogenous retrovirus, TGEV: Transmissible gastroenteritis 
coronavirus) 
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As explained in our study on hygiene sanitation during the population of CiMM, we did not 
only screen for PCMV but also for a various number of other pathogens, listed exemplary in 
Table 12 (EGERER et al., 2018). Within the study, the 91 F1 piglets, and consequently all gilts 
which became ET recipients, were monitored very tightly over a period of 14 months. This 
extent has not been achieved in the F2 generation, i.e. the first gm offspring, due to several 
reasons. First, the sequential farrowing of ET recipients logistically complicated the sampling 
of each animal at the same age and prevented the testing of all animals at the same timepoint 
(Figure 8). Second, with increasing numbers of pigs in CiMM, individual testing becomes very 
cost-intensive and, third, the establishment of breeding herds out of only a few founding 
animals is a critical undertaking. Loss of animals needs to be avoided under any circumstance, 
which is further complicated when certain pig lines are stress sensitive such as the Duchenne 
muscular dystrophy (DMD) pig model (KLYMIUK et al., 2013) or Laron animals (HINRICHS et 
al., 2018). Thus, only partial blood sampling has been carried out on representative animals. 
Still, all of the 19 F2 animals tested in the study have been proven free of the tested pathogens. 
In the meanwhile, and during the continuing settlement of the different breeding lines, the 
test regimen is being continued according to the publication. The reduced frequency and scale 
of sampling is, importantly, not only dictated by the available resources at CiMM, but also 
according to the intentions of animal welfare: while the tight monitoring of animals during the 
population of CiMM was necessary to prove the effect of the sanitation, it would meanwhile 
resemble a significant burden for the animals without essential gain of knowledge. This 
condition might change, once donor animals for clinical xenotransplantation will be delivered, 
but at the moment the required hygiene standard has not been finally clarified. Furthermore, 
and according to the FDA “Guidance for Industry: Source Animal, Product, Preclinical, and 
Clinical Issues Concerning the Use of Xenotransplantation Products in Humans” (FDA, 2003) it 
might become obligatory to maintain donor animals separated from any other pigs that are 
not being dedicated for this purpose. Thus, at the present timepoint, maintenance and 
surveillance of a common hygiene standard for experimental animals under the “FELASA 
recommendations for the health monitoring of breeding colonies and experimental units of 
cats, dogs and pigs” (REHBINDER et al., 1998), is the opportune way to go, both, from the 
economic point of view as well as from the standpoint of animal welfare. 
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Table 12 Exemplary screening results table, adapted from the ones we receive from 
Vaxxinova. (Vaxxinova GmbH, Münster, Germany) 
 
 
 
 
Figure 8 Showing coarsely the different sampling time-points for Vaxxinova and the Robert- 
Koch-Institute (RKI) of the three different pig generations, populating CiMM to establish a 
PCMV free pig herd. 
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5.3 Novel pathogens to be considered for donor herd safety 
 
Eventually, the definition of a test regimen will depend on the responsible authority, which in 
Germany is the Paul-Ehrlich-Institut (PEI). Evidently, any initial test regimen definition will be 
based on the expert opinions in the field, but evidently as well, the requirements for testing 
animals will be refined after initial definition, according to the Fishman statement “It seems 
likely that the way in which the level of safety is achieved need not be uniform so long as the 
transplanted tissues do not pose a microbiologic hazard to the recipient”(FISHMAN, 2018). The 
recent discovery of Porcine Circovirus 3 (PCV3), a new possible pathogen in our previous 
breeding herd at LVG (KRUGER et al., 2019) might serve as a good example for developing 
standards in hygiene monitoring. PCV3 was first described in 2016 in pigs with cardiac and 
multi-systemic inflammation (PHAN et al., 2017), in mummified fetuses aborted from sows 
with porcine dermatitis and nephropathy syndrome (PDNS)-like lesions and in sows that died 
acutely with PDNS-like clinical signs (PALINSKI et al., 2017). However, PCV3 is not a new virus , 
but has been found in retrospective studies on samples dating back to 1993 in Sweden (YE et 
al., 2018) and to 1996 in Spain (KLAUMANN et al., 2018) and China (SUN et al., 2018). Although 
so far, the relevance of PCV3 for xenotransplantation remains elusive, its recent appearance 
in pig populations illustrates the dynamics of pathogen evolution. It is their very nature that 
viruses in general, and circoviruses in particular, are genetically diverse and can infect a wide 
range of hosts, with documented cross-species transmission (LI et al., 2010; LI et al., 2011). 
For better understanding the forces behind the latter, the idea of a “host‐agent‐environment 
triangle” has been developed (reviewed in DAVIES, 2012). This is a conceptual model that 
takes into account the interactions between environment, host and an infectious (or abiotic) 
agent (SCHOLTHOF, 2006). This model can be used to predict epidemiological outcomes in 
plant health and public health and was first established by George McNew in the 1960s 
(MCNEW, 1960). According to McNew, six interacting factors determine the development of 
an economically important disease: the climate of the physical environment (for example 
drought or humidity), the duration of the infection period, prevalence of the pathogen, 
virulence of the pathogen, the age or maturity of the host and its particular susceptibility to 
disease. By reduction to these parameters a host-agent-environment triangle can be used as 
a predictor of new or variant pathogens, spreading in a dense population, which definitely 
reflects the present conditions of agricultural pig housing. In addition, in the growing 
agricultural sector, genetic selection of the potential host species has led to almost genetic 
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uniformity (EDFORS-LILJA et al., 1998), which must also be considered as essential factor for 
disease resistance and the development of newly emerging diseases. Livestock production in 
large herds represents an excellent environment to alleviate the transmission and expansion 
of viruses, contributing to the pathogen evolution through mutation, recombination and 
reassortment (NICHOL et al., 2000; LA ROSA et al., 2012; CORREA-FIZ et al., 2018). The 
continuing intensification of agricultural production might have been a major driver for 
establishing PCV3 in the pig, and the extensive exchange of animals, human beings being in 
contact with the animals, and material from agricultural facilities might have supported the 
spreading of PCV3 in pig population all over the planet. Therefore, raising large livestock herds 
without implementing enhanced biosecurity may lead to populations particularly vulnerable 
to disease emergence (PULLIAM JULIET et al., 2012) (reviewed in DAVIES, 2012). Emerging 
disease events, particularly in Asia, underline the importance of biosecurity measurements, 
as it still remains a hot-spot for novel zoonotic diseases, arising from inter-species contact, for 
example new influenza strains (WEBSTER, 2002), Nipah virus (PULLIAM JULIET et al., 2012) or 
SARS (LI et al., 2005). In contrast to the situation in Asia, where inter-species contact is 
common and enables the development of zoonotic diseases, the trend in developed countries 
has led to increased herd sizes with only one species kept, condensed at one place. As a 
consequence of dense livestock populations, pathogens often show high virulence in 
individual species, but due to the diminished inter-species contact, pathogens appear 
relatively host specific (reviewed in DAVIES, 2012). However, recent findings show that this is 
not true in all cases. For example, porcine circovirus type 1 (PCV1) and porcine circovirus type 
2 (PCV2) have been shown to infect human cells (HATTERMANN et al., 2004; LIU et al., 2019) 
and thus circoviruses may pose a risk on a xenotransplant recipient (reviewed in DENNER & 
MANKERTZ, 2017). For PCV3 the picture is less clear. Evidently, the virus was also found in wild 
boars (FRANZO et al., 2018a; KLAUMANN et al., 2019; PRINZ et al., 2019) and it is suggested 
that wild boars may be a potential reservoir for PCV3 infection. To fill the missing 
epidemiological data, plenty of studies were carried out to expand the knowledge on PCV3 
evolution, transmission, spreading patterns and impact on pig health. It was possible to detect 
PCV3 by PCR in nasal swabs (FRANZO et al., 2018c), oral fluids (KWON et al., 2017), feces 
(COLLINS et al., 2017; KLAUMANN et al., 2019), semen (KU et al., 2017), in sow colostrum 
(KEDKOVID et al., 2018) and even in sponges collected from trucks after sanitation (FRANZO 
et al., 2018b). Further, PCV3 was detected in dog sera in China (ZHANG et al., 2018) and in all 
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organs of the recipient baboons in the pig-to-primate xenotransplantation model (KRUGER et 
al., 2019), which suggests trans-species transmission. But up to now, there is no other (than 
these two) evidence that PCV3 is capable of infecting other species. It can be only s uggested, 
that there was replication of PCV3 in the baboons, since the virus was found in all organs from 
the four baboons and the virus load increased with the survival time (KRUGER et al., 2019). As 
“transmission” describes the way or circumstances a pathogen needs to get from its current 
host to the next healthy individual and there are five big categories of means of transmission: 
contact, food- or water-borne, air-borne, vector-borne and perinatal (NELSON et al., 2001) 
and PCV3 was further detected on so many different body fluids and even sponges, it can 
hardly be guessed which transmission routes PCV3 takes. 
Regarding xenotransplantation, transmission, infection and disease potential of PCV3 remains 
totally unclear at the moment. Experiments to infect human cell line 293 were not successful 
in our study (KRUGER et al., 2019), but does evidently not prove that PCV3 is not capable of 
infecting any human cells at all. Further investigations have to be done to understand the 
possible risk that PCV3 may pose on xenograft recipients, but at the moment it appears that 
testing for PCV3 in our breeding herd might be senseful, but not ultimately necessary. 
 
5.4 Heredity of PERV-C proviruses in our xenotransplantation donor herd 
 
Due to their endogenous nature, PERVs resemble a special aspect of xenotransplantation 
safety. Their integral constitution in the genome complicates their removal. A very important 
aspect is also that the threat that PERVs are representing is not fully clear. Evidently, the 
infection assays that have been documented decades ago (ARMSTRONG et al., 1971; LE 
TISSIER et al., 1997; PATIENCE et al., 1997; TAKEUCHI et al., 1998; SCOBIE & TAKEUCHI, 2009), 
were so far not confirmed by in vivo experiments. Evaluation of clinical xenotransplantation 
studies using capsulated islet grafts did not show evidence for virus transmission to patients 
(GARKAVENKO et al., 2004b; WYNYARD et al., 2014; MOROZOV et al., 2017; reviewed in 
DENNER, 2018).In addition, there is no animal model displaying the in vivo trans-species 
transmission situation of PERVs, and until now, no assays for monitoring and for the detection 
of PERV transmission in vivo have been certified. However, it is clearly recommended to use 
PERV-C free animals as donors for xenotransplantation, to avoid the possibility of recombinant 
PERV-A/C occurrence (DENNER et al., 2009). We therefore wanted to assess the amount of 
PERV-C in our herd of donor pigs for xenotransplantation. We could not identify any PERV-C 
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in the reference genome of the pig by scanning it with the env sequence, whereas PERV-C 
proviruses were found when examining the reference genome for the associated LTR 
sequences. The finding, that some of these LTR descend from truncated proviruses, raised the 
question how these truncated proviruses (the proviruses chr.14:62.55, chr.11:29.09, 
chr.2:0.23 and scf141) could have colonized the genome of the pig. A very important hallmark 
of endogenization of retrovirus is its integration into the genome of germ cells after which the 
retrovirus can endure as stable provirus for multiple generations (BOEKE & STOYE, 1997). A 
typical sign for retroviral integrase activity, amongst others, is a duplication of a certain 
number of host bp DNA (HISHINUMA et al., 1981), being characteristic for different viruses, 
for example, a 6 bp duplication for avian sarcoma/leukosis virus (ASLV), 4 bp duplication for 
MLV and 5 bp duplication for HIV-1 (reviewed in ANDRAKE & SKALKA, 2015). Although there 
are studies that suggest that solo-LTR, the most truncated form of a provirus, can amplify in 
the genome via classical retrotransposition (HEIDMANN et al., 1988; JUNGMANN & TÖNJES, 
2008), we conclude from the consistent 4 bp duplication in their flanking region, that the 
truncated proviruses, similar to the full-length PERV-C, have entered the pig genome by 
retroviral integration. It is clear that a truncation of the env gene might have happened during 
reverse transcription, after a retroviral particle has entered a germ cell or that, even later, the 
truncation has occurred at the proviral stage. In both cases, such a provirus might then 
represent an evolutionary dead end, from the retroviral point of view, being incompetent for 
replication. The finding that all truncated PERV-C-like proviruses have an identical gap in the 
env gene, however, challenge this terminal faith hypothesis. As the provirus is truncated and 
lacks parts of its env gene, an amplification by retroviral re-infection depends on the 
generation of infectious particles by intact proviruses and the packaging of the truncated 
proviral transcript into such particles. From such particles new truncated proviruses might 
accumulate in germ cells after infection and reverse transcription. Although I did not find 
evidence in the literature for such a “hitchhiking” scenario, this is the most conclusive 
explanation for our finding of independent retroviral integration of truncated proviruses. 
Another interesting aspect of our examination of PERV-C is the timepoint of their integration. 
Based on the molecular-clock hypothesis (reviewed in HO & DUCHENE, 2014) the age of a 
provirus can be estimated by the mutations in the two LTR sequences flanking the proviral 
genome, as they develop separately from each other after integration into the host’s genome 
(KLYMIUK et al., 2006). It has been estimated that PERVs persists in the pig genome for 7.6 
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million years, at most (TONJES & NIEBERT, 2003). The fully identical LTR pairs of the full length 
PERV-C and the maximum number of 4 mismatches between the LTR in truncated proviruses, 
however, suggests a much younger age of this specific subfamily. This is also consistent with 
the very diverse pattern of PERV-C integration sites in our breeding herd. Of note, none of the 
PERV-C proviruses were found in all animals. Even, if it is considered that our breeding herd is  
a mixture of different more or less “modern” agricultural breeds, such as German Landrace, 
German Large-White, Duroc, Piétrain, Schwäbisch-Hällisch, and others, and might have 
introduced the different proviruses, these breeds are quite young in evolutionary terms, very 
likely a few hundred years at most. Although, the domestication lineages of European pig 
breeds are difficult to follow and might have been mixed occasionally with wild-boar genomes 
(FRANTZ et al., 2019), it is likely that PERV-C proviruses have not only entered the genome of 
domestic pigs via domestication of wild-boars, but also via infection in agricultural pigs. 
By following the different PERV-C provirus integration sites in the animals used for 
establishing and maintaining the breeding herd at MABB, we revealed that the different PERV- 
C provirus integration sites were inherited vertically from parents to offspring in a Mendelian 
manner (Figure 7), which is consistent to endogenous retroviruses in chicken and mouse lines 
(VOGT, 1997; PATIENCE et al., 2001). Together with the finding that none of the PERV-C 
proviruses is present in all animals, this is an extremely useful finding because, this would 
facilitate the outbreeding of PERV-C proviruses from our donor pigs for xenotransplantation. 
Although, this would be a really time-consuming approach, limited in its power by the low 
numbers of animals produced, and the difficulties to balance the desire for low PERV-C copy 
numbers with the required combination of genetic modifications when choosing future 
breeding animals. Still, the proven feasibility to get rid of PERV-C simply by breeding makes 
this approach practicable, whereas alternatives such as the excision of given PERV-C 
proviruses (see Doctoral thesis “Deleting PERV-C infectious potential of donor pigs for 
xenotransplantation” by Ingrid Kola) or the global inactivation of PERV by deleterious 
mutations within the provirus (YANG et al., 2015; NIU et al., 2017) resemble a tremendous 
effort. In the future perspectives of generating novel models for xenotransplantation from 
scratch, it is also relevant to have PERV-C free individuals identified, as such will form the basis  
of generating PERV-C-free genetically modified lines. 
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5.5 Anti-Gal antibodies – a vital heritage 
 
Immunosurgery is a very sophisticated and effective way to isolate the inner cell mass (ICM) 
from blastocysts, by complement-mediated lysis of the antibody-coated trophectoderm (TE), 
but the choice of the antiserum is one of the most critical factors determining the isolation 
efficiency (KUROME et al., 2019). As the enzyme GGTA1 is functional in most species, but not 
in Old World Monkeys, apes and men (GALILI et al., 1988b; GALILI, 1993), the usage of serum 
of GTKO pigs and therefore the anti-Gal antibodies contained in the serum of these pigs, are, 
in contrast to the previously used antisera in the field of immunosurgery, well defined to one 
specific epitope and applicable to all species that express αGal epitopes (KUROME et al., 2019). 
The serum from our GTKO pigs, collected for this study, proved as a reliable and effective 
source of anti-Gal antibodies to target the αGal epitopes on the surface of the blastocysts from 
the different (mammalian) species used in this study. Even the youngest GTKO pigs, with only 
5 months, had enough natural anti-Gal antibodies in their serum to induce complement- 
mediated lysis, though the serum of a two-year-old pig, showed an even stronger activity, 
which indicates, that the number of antibodies circulating in the blood increases over the time. 
This is in line with the idea that individuals lacking the αGal epitopes start to produce anti-Gal 
antibodies at a very early stage in life, after immune stimulation by bacterial carbohydrate 
epitopes at the age of 6 weeks (DOR et al., 2004; FANG et al., 2012; GALILI, 2013). 
Of note, the effect we took advantage of, namely that anti-Gal antibodies induce complement- 
mediated lysis resembled its very natural function, the destruction and neutralizing of viruses 
presenting αGal epitopes which was seen in murine C retrovirus (ROTHER et al., 1995), PERV 
(TAKEUCHI et al., 1996), pseudorabies virus (HAYASHI et al., 2004), HIV (NEIL et al., 2005) and 
some others. This leads to the suggestion, that Old World Monkeys, apes and men, who are 
the only ones that lack the αGal epitopes, but produce natural anti-Gal antibodies somehow 
took advantage of this situation. The present theory about this advantage is, that an 
evolutionary mechanism named “catastrophic-selection” (LEWIS, 1962), by which entire 
parental populations are replaced by very few mutated offspring, which manage to survive a 
natural disaster, for example extinction by viral epidemics, took place 20-30 million years ago 
(reviewed in GALILI, 2019). Here, the parental population of ancestral Old World Monkeys and 
apes were replaced by their GTKO offspring, who was capable of destroying the viruses 
circulating, and thus was protected from extinction. Later in evolutionary history, the same 
scenario was repeated when early ancestors of Homo sapiens, synthesizing N-5-glycolyl- 
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neuraminic acid (Neu5Gc), were replaced by offspring lacking Neu5Gc and instead now only 
synthesizing N-acetyl-5-neuraminic acid (Neu5Ac), because of inactivation of their cytidine- 
monophosphate-N-acetyl-neuraminic acid hydroxylase (CMAH) gene (SHAW & SCHAUER, 
1989; CHOU et al., 1998; IRIE et al., 1998; MUCHMORE et al., 1998; VARKI, 2010; SPRINGER et 
al., 2014). The event of catastrophic-selection sets apart from Darwinian natural selection and 
from genetic drift, as they occur as gradual changes during many generations, as a result from 
continuous selection (reviewed in GALILI, 2019), whereas in catastrophic-selection, one 
mutation accidentally appearing in a very small population of offspring, leads to resistance in 
a selective event that eliminates all of the parental population, lacking the required mutation 
within a short period of time. The synthetization of αGal epitopes in nonprimate mammals, 
lemurs and New World Monkeys indicates, that ancestral Old World Monkeys and apes were 
also capable of synthesizing αGal epitopes in early periods after the split from New World 
Monkeys, which is estimated to have occurred about 30-43 million years ago (STEIPER et al., 
2004; SCHRAGO et al., 2013), but they went extinct, as mentioned above, because of lethal 
virus infection, most likely by an airborne, highly virulent, enveloped virus. These enveloped 
viruses have phospholipids and glycoproteins which form together the envelope (GALILI et al., 
1996). To synthesize the carbohydrate chain portion of the glycoproteins, the virus depends 
on the enzymes of the Golgi apparatus of the host (ROBBINS et al., 1977; KORNFELD & 
KORNFELD, 1985). The glycosyltransferases in the host’s Golgi apparatus add carbohydrate 
units to the developing chain of glycoproteins as it moves through the compartments of the 
Golgi apparatus. GGTA1 adds the terminal galactose, provided by uridine-diphosphate 
galactose (UDP-Gal), synthesizing the αGal epitope on cellular, as well as on viral carbohydrate 
chains (GEYER et al., 1984; REPIK et al., 1994). Consequently, these viruses, which infected 
cells containing active GGTA1 had multiple αGal epitopes on their envelope gylcoproteins 
(GALILI et al., 1996; PATIENCE et al., 1997; DURRBACH et al., 2007). Thus, the virulent 
enveloped viruses, provided with αGal epitopes by the ancestral parental primate population 
were then neutralized and destroyed by the offspring that lost this epitope and produced anti- 
Gal antibodies, in contrast to their parental generation, which were susceptible to the viruses  
and underwent extinction. 
Evidently, the possibility of genetically modifying genomes facilitates the recapitulation of an 
evolutionary process. The tailoring of donor pigs for xenotransplantation by disruption of 
genes involved in the glycosylation process can be seen as the bringing together of genetic  
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constellations that drifted apart by natural selection. It is of note, however, that evolutionary 
fundamental events such as the deletion of the GGTA1 gene in old-world primates are rare 
and manifest within generations. In much shorter terms, evolution is quite stable. This is 
illustrated by the stable inheritance of the hCD46 and the hTBM transgenes in our breeding 
herd for meanwhile 8 generations. Moreover, the expression profile of the transgenes, and 
thus, the quality of the donor pigs remains stable through many generations of breeding 
(LANGIN et al., 2018). Therefore, it is not necessary to produce xenotransplantation donor 
animals by SCNT, but to provide them in a rather easy way, by breeding. 
6 SUMMARY 110 
 
 
6 Summary 
 
With the growing demand for deceased organ donors and the steady increase of an aging 
population, a solution to the organ shortage has to be found. Xenotransplantation can offer a 
feasible solution within the near future, based on the potential, documented in recent 
preclinical trials. To further promote these perspectives, the aim of this doctoral thesis was to 
evaluate and improve the hygiene status of donor pigs for preclinical trials of collaboration 
projects embedded in the CRC TRR 127. 
Major parts of my work on hygiene sanitation have been done during the population of a new 
facility, the Center of innovative Medical Models (CiMM), at the Chair of Molecular Animals 
Breeding and Biotechnology (MABB) (EGERER et al., 2018). For this, pregnant DPF sows from 
a barrier facility were introduced to the new facility, CiMM, and quickly removed after 
farrowing, with the piglets only being able to suckle colostrum every 2 hours for 24 hours 
under supervision, to avoid any further contact with the mother sows. The motherless reared 
female piglets became the foster mothers of SCNT and IVF derived genetically-multimodified 
pig lines, which were introduced solely by embryo transfer (ET). With this approach we were 
able to establish a PCMV-free pig facility. But not only screening for PCMV was done, in the 
progress of the herd sanitation we screened for other exogenous pathogens, as listed in Table 
12 . 
Another step for the provision of safe donor pigs is the continuing assessment of potential 
new threats for xenograft recipients, as it was exemplified by the detection of PCV3 in our 
herd and in four baboons, after being transplanted with infected porcine hearts (KRUGER et 
al., 2019). Permanent maintenance of a breeding herd for xenotransplantation donors is, 
however, necessary for the constant supply of safe donor pigs, which is one of the essential 
prerequisites for robust pre-clinical studies, as it has been recently documented in a 
groundbreaking pig-to-baboon heart transplantation study (LANGIN et al., 2018). The 
continuous production of pigs by breeding was also a good opportunity to address another 
safety aspect in xenotransplantation, the abundance of PERVs, specifically of the subfamily C. 
I was clearly able to document that none of the PERV-C proviruses was abundant in all animals 
and that the proviruses are inherited in a Mendelian manner. In some of the animals this 
resulted in a PERV-C free status, suggesting that breeding-out of PERV-C is possible, albeit this  
will take some time, due to the low number of animals being produced and the long 
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generation time of pigs. Another remarkable finding was, that there are truncated PERV-C 
proviruses, which have very likely accumulated in the pig genome by retroviral hitchhiking, as 
the respective proviruses were flanked by 4 bp duplications, a very characteristic feature of 
retroviral infection. Finally, the presence of breeding herds for xenotransplantation facilitated 
also the ability to gain materials for other projects. A good example for that, was a study on 
immunosurgery of blastocysts, which is profoundly promoted by serum the from GTKO pigs, 
which contains high levels of anti-Gal-antibodies to induce complement-mediated lysis of 
blastocysts, expressing the αGal epitope (KUROME et al., 2019). 
Thus, my doctoral thesis illustrates the high relevance of continuous production of genetically 
modified pigs for xenotransplantation by breeding and documents the ability to remove 
exogenous as well endogenous pathogens from an existing herd. These findings will be 
essential aspects for paving the way towards eventually supplying donor pigs also for clinical 
research. 
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7 Zusammenfassung 
 
Bereitstellung sicherer Spenderschweine für die Xenotransplantation 
 
Aufgrund des steigenden Bedarfs an Organen verstorbenen Organspendern und einer stetig 
wachsenden und alternden Bevölkerung, muss eine Lösung für diese Spenderorganknappheit 
gefunden werden. Die Xenotransplantation könnte hierfür eine machbare Lösung in naher 
Zukunft sein, was sich auf den Leistungen begründet, die in der aktuellen vorklinischen 
Forschung dokumentiert wurden. Um diese Aussichten weiter voranzutreiben, war das Ziel 
dieser Doktorarbeit, den Hygienestatuts von Spenderschweinen für präklinische 
Forschungsprojekte innerhalb des Sonderforschungsbereich 127 zu evaluieren und zu 
verbessern. 
Große Teile meiner Arbeit an der Hygienesanierung, fanden während der Neubesiedlung 
unserer neuen Stallanlage, dem „Center of innovative Medical Models (CiMM) am Lehrstuhl 
für Molekulare Tierzucht und Biotechnologie (MABB), statt (EGERER et al., 2018). Dafür 
wurden trächtige DPF Sauen von einer Stallanlage mit strikt geregeltem und eingeschränktem 
Zugang, in unsere neue Anlage, CiMM, gebracht und sofort nach dem Abferkeln wieder 
entfernt, wobei die Ferkel für 24 Stunden alle 2 Stunden Kolostrum unter Aufsicht trinken 
konnten, um jeglichen weiteren Kontakt mit den Muttersauen zu vermeiden. Die mutterlos- 
aufgezogenen weiblichen Ferkel wurden Ziehmütter von SCNT und IVF generierten, genetisch- 
multimodifizierten Schweinelinien, die ausschließlich durch Embryotransfer (ET) eingebracht 
wurden. Durch diese Herangehensweise konnten wir einen PCMV-freien Schweinestall 
aufbauen. Außerdem wurde nicht nur auf PCMV untersucht, sondern während der 
Herdenerneuerung und -bereinigung, wurde auch auf andere exogene Pathogene untersucht, 
die in Table 12 aufgeführt sind. 
Der nächste Schritt, bei der Bereitstellung von sicheren Spenderschweinen, ist die 
fortlaufende Einschätzung potenzieller neuer Gefahren für Xenotransplantatempfänger, wie 
es der Nachweis von PCV3 in unserer Herde und in vier Pavianen, nach der Transplantation 
mit infizierten Schweineherzen, veranschaulicht hat (KRUGER et al., 2019). Die andauernde 
und fortlaufende Instandhaltung einer Zuchtherde von Spenderschweinen für die 
Xenotransplantation ist, trotz allem und gerade für die konstante Versorgung mit sicheren 
Spenderschweinen, eine notwendige, essentielle und unabdingbare Grundvoraussetzung für 
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robuste präklinische Studien, wie es kürzlich erst gezeigt wurde, in einer wegweisenden 
Schwein-zu-Pavian Herztransplantationsstudie (LANGIN et al., 2018). Die ständige Nachzucht 
von Schweinen, durch Unterhaltung einer Zuchtherde, war auch eine gute Möglichkeit, um 
einen anderen Sicherheitsaspekt der Xenotransplantation, die Anzahl von PERVs, im 
Speziellen von der Unterfamilie C, zu behandeln. Es war mir möglich klar zu dokumentieren, 
dass keiner der PERV-C Proviren in allen Tieren vorkam und dass die Proviren nach den 
Mendelschen Regeln vererbt werden. Bei manchen Tieren führte das zu einem PERV-C freien 
Status, was die Schlussfolgerung zulässt, dass man PERV-C durch Zucht elimieren kann, 
wenngleich das einige Zeit dauern wird, wegen der geringen Tierzahlen die produziert werden 
und der langen Generationsdauer von Schweinen. Eine weitere hervorzuhebende Erkenntnis 
war, dass es „kaputte“ PERV-C Proviren gibt, die sich höchstwahrscheinlich als retroviraler 
Anhalter/Mitfahrer im Schweinegenom angereichert haben, da die betreffenden Proviren von 
4bp Verdoppelungen flankiert waren, was ein charakteristisches Zeichen für eine retrovirale 
Infektion ist. Zuletzt hat die Existenz von Zuchtherden für die Xenotransplantation die 
Möglichkeit gegeben, Material für andere Projekte zu sammeln. Ein gutes Beispiel ist die 
Studie über „Immunchirurgie“ an Blastozysten, die ungemein vom Serum der GTKO 
Schweinen profitiert hat, da das Serum hohe Level an anti-Gal-Antikörpern enthält, welche die 
Komplement-mediierte Lyse von Blastozysten, die αGal-Oberflächenepitope exprimieren, 
induzieren (KUROME et al., 2019). 
Folglich veranschaulicht meine Doktorarbeit die hohe Relevanz der kontinuierlichen 
Produktion genetisch-modifizierter Schweine für die Xenotransplantation durch Zucht und 
belegt, dass man sowohl exogene, als endogene Pathogene von einer bereits existierenden 
Herde beseitigen kann. Um den Weg für eine mögliche Bereitstellung von Spenderschweinen 
auch für die klinische Forschung, zu ebnen, werden diese Erkenntnisse essentielle 
Gesichtspunkte sein. 
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were extracted from the genome and aligned. The tree is based on a maximum likelihood tree, 
with branches occurring also in most parsimony depicted in bold and branch nodes that 
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Pig 
 
Day 1 
 
Day 6 
 
Day 12 
 
Day 26 
 
Day 50 
 
Day 73 
 
Day 135 
 
Day 230 > 1 Year † 
#1 –§ – – – – dead    
#2 – – – – – – – dead  
#3 – dead        
#4 – – – – – – – – dead 
#5 – dead        
#6 – – – – – – – – – 
#7 – – – – – – – – – 
#8 – – – – – – – – – 
#9 – – – – – – – – dead 
#10 – – – – – – – – n.d. ‡ 
#11 – dead        
#12 dead         
#13 – – – – – – – dead  
#14 – dead        
#15 – – – – – – – – – 
#16 – dead        
#17 – – – – – – – – dead 
#18 – – – – – – – – dead 
#19 – – – – – dead    
#20 – dead        
#21 – – – – – – – – – 
#22 – – – – – – – – – 
#23 – – – – – – – dead  
#24 – – – – – – – – n.d. 
#25 – – – – – – – dead  
#26 – – – – – – – – dead 
#27 – – – – – – – dead  
#28 – – – – – dead    
#29 – – – – – – – – – 
#30 – – – – – – – – n.d. 
#31 – – – – – – – – – 
#32 – – – – – dead    
#33 – – – – – – – dead  
#34 – – – – – – – dead  
#35 – – – – – dead    
#36 – – – – – – – dead  
#37 – – – – – – – – – 
#38 – – – – – – – – n.d. 
#39 – – – – – – – – n.d. 
#40 – – – – – – dead   
#41 – – – – – – – – n.d. 
#42 – – – – – – – – – 
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#43 – – – – – – – – – 
#44 – – – – – – – – – 
#45 – – – – – – – – – 
#46 – – – – – – – – – 
#47 – dead        
#48 – – – – – – – – – 
#49 – – – – – – – – n.d. 
#50 – – – – – – – – – 
#51 – dead        
#52 – – – – – – – – – 
#53 – – – – – – – – – 
#54 – – – – – – – – – 
#55 – – – – – – – – dead 
#56 – – – – – – – – – 
#57 – dead        
#58 – – – – – – – – – 
#59 – – – – – dead    
#60 dead         
#61 – – – – – – dead   
#62 – – – – – – – – n.d. 
#63 – – – – – dead    
#64 – – – – – – – – – 
#65 – – – – – – – – – 
#66 – – – – – – – – – 
#67 – – – – – – – – – 
#68 – – – – – – – – – 
#69 – – – – – – – – – 
#70 – – – – – – – – – 
#71 – – – – – dead    
#72 – – – – – – – – – 
#73 – – – – – – – – dead 
#74 – – – – – – – – n.d. 
#75 – – – – – – dead   
#76 – – – – – – – – dead 
#77 – – – – – – – – n.d. 
#78 – dead        
#79 – – – – – – – – – 
#80 – dead        
#81 – dead        
#82 – dead        
#83 – dead        
#84 – – – – – – dead   
#85 – – – – – – dead   
#86 – dead        
#87 – – – – – – – – – 
#88 dead         
#89 dead         
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#91 – – – – – – – – n.d. 
 
† tested on DNA extracted directly from tissue, blood or serum without PBMC cultivation  
‡not determined 
§negative result 
 
SUPPLEMENTARY TABLE 1 PCMV screen of all F1 generation offspring. 
F1 generation offspring was screened at regular intervals over the whole observation period 
of 14 months. All F1 animals are negative for PCMV at all tested time points. (Taken from 
EGERER et al., 2018) 
#90 – dead 
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number 
chr1:20 chr1:41 chr1:3 chr2:10 chr4:135 chr5:23 chr6:41 chr7:18 chr11:29 chr13:104 chr14:62 Chr16:79 chrX:14 scf200 
LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV 
1410 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg 
1481 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg 
1511 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg pos pos 
1621 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg 
1622 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg 
1761 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
1929 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos pos pos neg pos neg pos neg pos neg pos neg 
1938 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
1974 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
2017 pos pos pos pos pos pos pos neg pos neg pos neg pos neg pos pos pos pos pos neg pos neg pos pos neg pos pos pos 
2041 neg pos pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
2074 pos pos pos pos pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg pos pos 
2909 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg 
3360 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos pos pos pos 
3603 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos pos pos neg pos pos 
4667 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos 
4679 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos 
4682 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
4686 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos 
4688 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos 
4689 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos 
4775 pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos pos neg pos pos neg pos neg pos pos pos pos pos neg 
4791 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg pos neg 
5004 neg neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
5006 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
5411 pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos pos neg pos pos neg pos neg pos neg pos neg pos pos 
5426 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
6182 pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos pos pos neg pos neg pos neg pos neg pos neg 
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6183 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg pos pos 
6184 pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos pos pos neg pos neg pos neg pos neg pos neg 
6185 pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg pos pos 
6186 pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos pos neg pos pos neg pos neg pos neg pos neg pos pos 
9781 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg pos neg 
9864 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg 
X101 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg 
X102 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos 
X126 pos pos pos pos pos pos pos neg pos neg pos neg pos neg pos pos pos pos pos neg pos neg pos pos pos neg pos pos 
X127 pos pos pos pos pos pos pos neg pos pos pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos 
X129 pos pos pos pos pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos neg pos pos 
X149 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos pos pos pos pos neg pos neg pos pos pos pos pos pos 
X155 pos neg pos pos pos neg pos neg pos pos pos neg pos neg pos pos pos pos pos neg pos neg pos pos pos pos pos pos 
Y108 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos pos 
1476 pos pos pos pos pos neg pos neg pos pos pos pos pos neg pos neg pos pos pos pos pos neg pos neg pos neg pos pos 
4504 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos pos neg pos pos neg pos neg pos pos pos pos pos neg 
4505 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos pos pos pos pos neg 
1044 pos neg pos neg pos pos pos neg pos pos pos neg pos neg pos neg n.d. neg pos neg n.d. n.d. pos neg pos neg pos neg 
3043 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg n.d. pos pos neg n.d. n.d. pos neg pos neg pos pos 
3047 pos neg pos neg pos pos pos neg pos pos pos neg pos neg pos neg n.d. pos pos neg n.d. n.d. pos neg pos neg pos pos 
9753 pos neg pos neg pos pos pos neg pos pos pos neg pos neg pos neg n.d. neg pos neg n.d. n.d. pos neg pos neg pos pos 
9781 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg n.d. pos pos neg n.d. n.d. pos neg pos neg pos neg 
9874 pos neg pos neg pos pos pos neg pos pos pos neg pos neg pos neg n.d. neg pos neg n.d. n.d. pos neg pos neg pos neg 
9875 pos neg pos neg pos pos pos neg pos pos pos neg neg neg pos neg n.d. neg pos neg n.d. n.d. pos neg pos neg pos pos 
9943 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg n.d. pos pos neg n.d. n.d. pos neg pos neg pos neg 
1476-Z pos pos pos pos pos pos pos neg pos pos pos pos pos neg pos neg n.d. neg pos pos n.d. n.d. pos pos pos neg pos pos 
4504-Z pos pos pos pos pos pos pos pos pos neg pos neg neg pos pos pos n.d. neg pos neg n.d. n.d. pos pos pos pos pos neg 
9869 neg neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg n.d. n.d. pos neg n.d. n.d. neg neg pos neg pos neg 
Table 13 All important animals from the pedigree shown in Figure 7 were examined for the presence of the 11 PERV-C and the 3 PERV-C-like proviral 
remnants. 
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number 
chr1:20 chr1:41 chr1:3 chr2:10 chr4:135 chr5:23 chr6:41 chr7:18 chr11:29 chr13:104 chr14:62 Chr16:79 chrX:14 scf200 
LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV LTR PV 
6202 pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos pos pos neg pos neg pos neg pos pos WT pos 
6203 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg neg pos WT pos 
6204 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos pos pos neg WT pos 
6205 pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos pos neg pos pos neg pos neg pos pos pos neg wt/lt neg 
6206 pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6207 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos pos neg pos pos neg pos neg pos neg neg pos wt/lt neg 
6208 pos neg pos neg pos neg pos neg pos pos neg neg pos neg pos pos neg pos pos neg pos neg pos neg pos pos WT pos 
6209 pos pos pos neg pos neg pos neg pos pos neg neg pos neg pos pos neg pos pos neg pos neg pos neg pos pos WT pos 
6210 pos pos pos neg pos neg pos neg pos pos neg neg pos neg pos neg neg pos pos neg pos neg pos pos pos pos WT pos 
6211 pos neg pos neg pos neg pos neg pos pos neg neg pos neg pos pos pos pos pos neg pos neg pos pos pos pos WT pos 
6246 pos pos pos neg pos neg pos neg pos neg neg neg pos neg pos pos neg pos pos neg pos neg pos neg pos neg WT neg 
6247 pos neg pos neg pos neg pos neg pos pos neg neg pos neg pos pos neg pos pos neg pos neg pos neg pos neg wt/lt neg 
6248 pos neg pos neg pos neg pos neg pos neg neg neg pos neg neg pos neg pos pos neg pos neg neg neg pos neg wt/lt neg 
6249 pos neg pos neg pos neg pos neg pos neg neg neg pos neg pos pos pos pos pos neg pos neg pos neg pos neg WT neg 
6250 pos neg pos neg pos neg pos neg pos neg neg neg pos neg pos pos neg pos pos neg pos neg pos neg pos neg wt/lt neg 
6251 pos neg pos neg pos neg pos neg pos pos neg neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6252 pos neg pos neg pos neg pos neg pos neg neg neg pos neg pos pos neg pos pos neg pos neg pos neg pos neg WT pos 
6253 pos neg pos neg pos neg pos neg pos neg neg neg pos neg pos pos pos pos pos neg pos neg pos neg pos neg WT pos 
6254 pos neg pos neg pos neg pos neg pos neg neg neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6255 pos pos pos neg pos pos pos neg pos neg neg neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg WT neg 
6256 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos neg WT pos 
6257 pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6258 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg WT neg 
6259 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6260 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT neg 
6261 pos neg pos neg pos pos pos neg pos neg neg neg neg neg pos neg pos neg pos neg pos neg pos pos pos neg WT neg 
6262 pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg WT pos 
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6263 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg WT pos 
6327 neg neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos neg WT pos 
6328 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6329 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6330 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6331 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos neg WT pos 
6332 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6333 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos neg WT pos 
6334 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6335 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos pos pos neg WT pos 
6336 pos pos pos neg pos pos pos neg pos neg neg neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6354 pos pos pos neg pos pos pos neg pos pos neg neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6355 pos pos pos neg pos pos pos neg pos neg neg neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6356 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6357 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6358 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6359 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6360 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6361 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6362 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6391 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT neg 
6392 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6393 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6394 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6395 pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT neg 
6396 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT neg 
6467 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6468 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT neg 
6469 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6470 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
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6471 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6472 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6473 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6474 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6475 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg wt/lt neg 
6492 pos neg pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg neg neg pos neg pos neg WT pos 
6493 pos pos pos neg pos pos pos neg pos pos pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6494 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg wt/lt neg 
6510 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT neg 
6511 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT neg 
6512 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6513 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6514 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6515 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg wt/lt neg 
6516 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT neg 
6517 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg wt/lt pos 
6518 pos neg neg neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT neg 
6519 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg wt/lt neg 
6520 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg wt/lt pos 
6521 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg neg pos pos neg pos neg pos neg pos neg WT pos 
6522 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6542 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6543 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6544 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6545 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6546 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6547 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6548 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6549 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6550 pos neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
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6551 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT pos 
6552 pos pos pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos pos pos neg pos neg pos neg pos neg WT pos 
6553 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT neg 
6554 neg neg pos neg pos pos pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT neg 
6555 pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg WT neg 
 
 
Table 14 Additionally to the important animals from the pedigree of Figure 7, all offspring was examined for the presence of the 11 PERV-C and the 
3 PERV-C-like proviral remnants, too. 
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